


**CUMULATIVE
SUPPLEMENT 2
FEBRUARY 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 2
February 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

CUMULATIVE SUPPLEMENT 2
February 2017

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)				
MULTISOURCE	15484 (85.4%)				
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)				
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)				
EXCEPTIONS ¹	73 (0.4%)				
NEW MOLECULAR ENTITIES APPROVED	7				
NUMBER OF APPLICANTS	1051				

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
 ACETAMINOPHEN

AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN

>A> AA NOVEL LABS INC 325MG;2.5MG A204407 001 Feb 24, 2017 Feb NEWA
 >A> AA 325MG;5MG A204407 002 Feb 24, 2017 Feb NEWA
 >A> AA 325MG;7.5MG A204407 003 Feb 24, 2017 Feb NEWA
 >A> AA 325MG;10MG A204407 004 Feb 24, 2017 Feb NEWA
 PERCOCET
 AA ! VINTAGE PHARMS LLC 325MG;7.5MG A040330 003 Nov 23, 2001 Jan CMS1
 AA ! 325MG;10MG A040330 004 Nov 23, 2001 Jan CMS1

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL
 ACETIC ACID 0.25% IN PLASTIC CONTAINER

>D> AT HOSPIRA 250MG/100ML N017656 001 Feb CAHN
 >A> AT ICU MEDCL 250MG/100ML N017656 001 Feb CAHN

ACYCLOVIR

CAPSULE;ORAL
 ACYCLOVIR
 @ CHARTWELL MOLECULES 200MG
 ZOVIRAX

AB +! MYLAN PHARMS INC 200MG N018828 001 Jan 25, 1985 Jan CAHN

SUSPENSION;ORAL
 ZOVIRAX

AB +! MYLAN PHARMS INC 200MG/5ML N019909 001 Dec 22, 1989 Jan CAHN

TABLET;ORAL
 ACYCLOVIR
 @ CHARTWELL MOLECULES 400MG
 @ 800MG
 ZOVIRAX

AB + MYLAN PHARMS INC 400MG N020089 001 Apr 30, 1991 Jan CAHN
 AB +! 800MG N020089 002 Apr 30, 1991 Jan CAHN

ADENOSINE

INJECTABLE;INJECTION
 ADENOSINE

AP WEST-WARD PHARMS INT 3MG/ML A076404 001 Jun 16, 2004 Jan CAHN
 AP 3MG/ML A076500 001 Jun 16, 2004 Jan CAHN
 @ 3MG/ML A076501 001 Jun 16, 2004 Jan CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>D> AN WATSON LABS EQ 0.083% BASE;0.017% A077063 001 Dec 31, 2007 Feb CAHN
 >A> AN WATSON LABS TEVA EQ 0.083% BASE;0.017% A077063 001 Dec 31, 2007 Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL
 ALPRAZOLAM

AB AUROBINDO PHARMA LTD 0.5MG A090871 001 Jun 07, 2011 Jan CAHN
 AB 1MG A090871 002 Jun 07, 2011 Jan CAHN
 AB 2MG A090871 003 Jun 07, 2011 Jan CAHN
 AB 3MG A090871 004 Jun 07, 2011 Jan CAHN
 >D> @ COREPHARMA 0.5MG A077996 001 Jan 31, 2007 Feb CAHN
 >D> @ 1MG A077996 002 Jan 31, 2007 Feb CAHN
 >D> @ 2MG A077996 003 Jan 31, 2007 Feb CAHN
 >D> @ 3MG A077996 004 Jan 31, 2007 Feb CAHN
 >A> @ IMPAX LABS INC 0.5MG A077996 001 Jan 31, 2007 Feb CAHN
 >A> @ 1MG A077996 002 Jan 31, 2007 Feb CAHN
 >A> @ 2MG A077996 003 Jan 31, 2007 Feb CAHN
 >A> @ 3MG A077996 004 Jan 31, 2007 Feb CAHN

AMANTADINE HYDROCHLORIDE

	SYRUP;ORAL					
	SYMMETREL					
	+ @ ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD
	TABLET;ORAL					
	AMANTADINE HYDROCHLORIDE					
AB	NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA

AMINO ACIDS

	INJECTABLE;INJECTION					
	AMINOSYN 10%					
>D>	HOSPIRA	10% (10GM/100ML)	N017673	003		Feb CAHN
>A>	ICU MEDCL	10% (10GM/100ML)	N017673	003		Feb CAHN
	AMINOSYN 10% (PH6)					
>D>	HOSPIRA	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb CAHN
>A>	ICU MEDCL	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb CAHN
	AMINOSYN 3.5%					
>D>	HOSPIRA	3.5% (3.5GM/100ML)	N017789	004		Feb CAHN
>A>	ICU MEDCL	3.5% (3.5GM/100ML)	N017789	004		Feb CAHN
	AMINOSYN 5%					
>D>	HOSPIRA	5% (5GM/100ML)	N017673	001		Feb CAHN
>A>	ICU MEDCL	5% (5GM/100ML)	N017673	001		Feb CAHN
	AMINOSYN 7%					
>D>	HOSPIRA	7% (7GM/100ML)	N017673	002		Feb CAHN
>A>	ICU MEDCL	7% (7GM/100ML)	N017673	002		Feb CAHN
	AMINOSYN 7% (PH6)					
>D>	HOSPIRA	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
>A>	ICU MEDCL	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
	AMINOSYN 8.5%					
>D>	HOSPIRA	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
>A>	ICU MEDCL	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
	AMINOSYN 8.5% (PH6)					
>D>	HOSPIRA	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
>A>	ICU MEDCL	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
	AMINOSYN II 10%					
>D>	HOSPIRA	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
>A>	ICU MEDCL	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
	AMINOSYN II 10% IN PLASTIC CONTAINER					
>D>	HOSPIRA	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
>A>	ICU MEDCL	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
	AMINOSYN II 15% IN PLASTIC CONTAINER					
>D>	HOSPIRA	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
>A>	ICU MEDCL	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
	AMINOSYN II 3.5%					
>D>	@ HOSPIRA	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
>A>	@ ICU MEDCL	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
	AMINOSYN II 5%					
>D>	@ HOSPIRA	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
>A>	@ ICU MEDCL	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
	AMINOSYN II 7%					
>D>	HOSPIRA	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
>A>	ICU MEDCL	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
	AMINOSYN II 8.5%					
>D>	HOSPIRA	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
>A>	ICU MEDCL	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
	AMINOSYN-HBC 7%					
>D>	HOSPIRA	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
>A>	ICU MEDCL	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
	AMINOSYN-PF 10%					
>D>	HOSPIRA	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
>A>	ICU MEDCL	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
	AMINOSYN-PF 7%					
>D>	HOSPIRA	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN
>A>	ICU MEDCL	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

>D>	HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N 017789	003			Feb	CAHN
>A>	ICU MEDCL	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N 017789	003			Feb	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

>D>	@ HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N 017789	005			Feb	CAHN
>A>	@ ICU MEDCL	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N 017789	005			Feb	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

>D>	HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N 017789	002			Feb	CAHN
>A>	ICU MEDCL	7%;102MG/100ML;522MG/100ML;410MG/100ML	N 017789	002			Feb	CAHN

AMINOSYN 8.5% W/ ELECTROLYTES

>D>	HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N 017673	005			Feb	CAHN
>A>	ICU MEDCL	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N 017673	005			Feb	CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A 075389	001	Jan 25, 2001		Jan	CAHN
	CORDARONE							
	+ @ WYETH PHARMS INC	200MG	N 018972	001	Dec 24, 1985		Jan	DISC

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

	+ @ RANBAXY	EQ 12% BASE	N 019155	001	Apr 24, 1985		Jan	CRLD
--	-------------	-------------	----------	-----	--------------	--	-----	------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

>D>	@ WATSON LABS	25MG	A 072418	001	May 11, 1989		Feb	CAHN
>D>	@	50MG	A 072419	001	May 11, 1989		Feb	CAHN
>D>	@	100MG	A 072420	001	May 11, 1989		Feb	CAHN
>D>	@	150MG	A 072421	001	May 11, 1989		Feb	CAHN
>A>	@ WATSON PHARMS TEVA	25MG	A 072418	001	May 11, 1989		Feb	CAHN
>A>	@	50MG	A 072419	001	May 11, 1989		Feb	CAHN
>A>	@	100MG	A 072420	001	May 11, 1989		Feb	CAHN
>A>	@	150MG	A 072421	001	May 11, 1989		Feb	CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

>D>	AB	DR REDDYS LABS INC	200MG/5ML	N 050760	001	Apr 15, 1999	Feb	DISC
>A>		@	200MG/5ML	N 050760	001	Apr 15, 1999	Feb	DISC
>D>	AB		400MG/5ML	N 050760	002	Apr 15, 1999	Feb	DISC
>A>		@	400MG/5ML	N 050760	002	Apr 15, 1999	Feb	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

>D>	AB	TEVA	125MG	A 064013	002	Sep 11, 1995	Feb	CTEC
>A>			125MG	A 064013	002	Sep 11, 1995	Feb	CTEC
>D>	AB	!	250MG	A 064013	001	Dec 22, 1992	Feb	CTEC
>A>		!	250MG	A 064013	001	Dec 22, 1992	Feb	CTEC
>D>		AMOXIL						
>D>	AB	DR REDDYS LABS INC	125MG	N 050542	002		Feb	DISC
>A>		+ @	125MG	N 050542	002		Feb	DISC
>D>	AB		250MG	N 050542	001		Feb	DISC
>A>		+ @	250MG	N 050542	001		Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

>D>		AUGMENTIN '200'							
>D>	AB	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb	DISC	
>A>		+ @	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb	DISC	
>D>		AUGMENTIN '400'							
>D>	AB	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb	DISC	
>A>		+ @	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb	DISC	
>D>		AUGMENTIN ES-600							
>D>	AB	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb	DISC	
>A>		+ @	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb	DISC	

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb	CHRS	
>A>	AB	!	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb	CHRS	
>D>	AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb	CHRS	
>A>	AB	!	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb	CHRS	
>D>		AUGMENTIN '250'							
>D>	AB	+!	DR REDDYS LABS INC 250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb	DISC	
>A>		+ @	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb	DISC	
>D>		AUGMENTIN '500'							
>D>	AB	+!	DR REDDYS LABS INC 500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb	DISC	
>A>		+ @	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb	DISC	

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb	CTEC	
>A>			200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb	CTEC	
>D>	AB	!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb	CTEC	
>A>		!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb	CTEC	
>D>		AUGMENTIN '200'							
>D>	AB	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb	DISC	
>A>		+ @	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb	DISC	
>D>		AUGMENTIN '400'							
>D>	AB	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb	DISC	
>A>		+ @	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb	DISC	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@	WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan	CAHN	
@		EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan	CAHN	
@		EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan	CAHN	
@		EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan	CAHN	
@		EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan	CAHN	
@		EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan	CAHN	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan	CAHN	
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan	CAHN	
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan	CAHN	

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

>A>	+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb	NEWA	
-----	----	--------------------	--------------------	---------	-----	--------------	-----	------	--

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORINAL

+ @	ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CRLD	
-----	--------------------	-----------------	---------	-----	--------------	-----	------	--

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	IMPAX LABS INC	25MG;200MG	A206964	001	Jan 18, 2017	Jan	NEWA	
AB	PAR PHARM INC	25MG;200MG	A207944	001	Jan 18, 2017	Jan	NEWA	
AB	SANDOZ INC	25MG;200MG	A206739	001	Jan 18, 2017	Jan	NEWA	

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

>D> @ WATSON LABS INC 10MG/ML A074945 001 Jul 28, 1998 Feb CAHN
>A> @ WATSON PHARMS TEVA 10MG/ML A074945 001 Jul 28, 1998 Feb CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

>D> AT ALCON PHARMA 0.05% A202305 001 May 31, 2012 Feb CAHN
>A> AT SANDOZ INC 0.05% A202305 001 May 31, 2012 Feb CAHN

SPRAY, METERED; NASAL
AZELASTINE HYDROCHLORIDE

>A> AB BRECKENRIDGE PHARM EQ 0.125MG BASE/SPRAY A090176 001 Jul 28, 2015 Feb CAHN
>D> AB BRECKENRIDGE PHARMS EQ 0.125MG BASE/SPRAY A090176 001 Jul 28, 2015 Feb CAHN

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

AP MYLAN LABS LTD EQ 500MG BASE/VIAL A204732 001 Jan 26, 2017 Jan NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
CORTISPORIN

>D> +! MONARCH PHARMS 400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM N050168 002 May 04, 1984 Feb CAHN
>A> +! 400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM N050168 002 May 04, 1984 Feb CAHN

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

>A> AA ! UPSHER-SMITH LABS 0.5MG A040103 001 Dec 12, 1996 Feb CAHN
>A> AA ! 1MG A040103 002 Dec 12, 1996 Feb CAHN
>A> AA ! 2MG A040103 003 Dec 12, 1996 Feb CAHN
>D> AA ! USL PHARMA 0.5MG A040103 001 Dec 12, 1996 Feb CAHN
>D> AA ! 1MG A040103 002 Dec 12, 1996 Feb CAHN
>D> AA ! 2MG A040103 003 Dec 12, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

AB ! FOUGERA PHARMS INC EQ 0.05% BASE A070275 001 Aug 12, 1985 Jan CAHN
DIPROSONE
+ @ SCHERING EQ 0.05% BASE N017781 001 Jan CRLD

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL
LUXIQ

AB +! MYLAN PHARMS INC 0.12% N020934 001 Feb 28, 1999 Jan CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

@ IMPAX LABS 5MG A040721 001 Nov 01, 2006 Jan CMS1
@ 10MG A040721 002 Nov 01, 2006 Jan CMS1
@ 25MG A040721 003 Nov 01, 2016 Jan CMS1

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE

AB ORIT LABS LLC 5MG A204891 001 Jan 11, 2017 Jan NEWA
AB 10MG A204891 002 Jan 11, 2017 Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC

AB + TEVA BRANDED PHARM 2.5MG; 6.25MG N020186 003 Mar 26, 1993 Jan CAHN
AB + 5MG; 6.25MG N020186 001 Mar 26, 1993 Jan CAHN
AB +! 10MG; 6.25MG N020186 002 Mar 26, 1993 Jan CAHN

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE

@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
---	----------------------	---------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

>D>	AT	ALCON PHARMS LTD	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
>A>	AT	SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

>D>	AT1	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS	
>A>	AT1	!	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS	
>D>	AT1	!	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb	DISC
>A>		@	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb	DISC	

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA	TARO	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
-----	----	------	-----------------------------	---------	-----	--------------	-----	------

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

AP		WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN
----	--	----------------------	-----------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

ZUBSOLV

+	OREXO US INC	EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
+	!	EQ 11.4MG BASE; EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

+	!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan	CAHN
---	---	---------	-------	---------	-----	--------------	-----	------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan	CAHN
AP			2MG/ML	A075045	002	Aug 12, 1998	Jan	CAHN

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+	!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan	CAHN
---	---	--------------	--------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	20MG/100ML; 5GM/100ML; 30MG/100ML; 60	N017608	001		Feb	CAHN	
>A>	AP	ICU MEDCL	0MG/100ML; 310MG/100ML						
>A>	AP		20MG/100ML; 5GM/100ML; 30MG/100ML; 60	N017608	001		Feb	CAHN	
>A>	AP		0MG/100ML; 310MG/100ML						
>D>		@	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
>D>		@	HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML;	N019685	005	Oct 17, 1988	Feb	CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

600MG/100ML; 310MG/100ML

>D> @ 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 N019685 006 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> @ ICU MEDCL 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 N019685 005 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> @ 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 N019685 006 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> @ HOSPIRA 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 N019685 007 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> @ ICU MEDCL 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 N019685 007 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AP HOSPIRA 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 N019685 002 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>D> AP 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 N019685 008 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> AP ICU MEDCL 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 N019685 002 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> AP 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 N019685 008 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> @ HOSPIRA 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 N019685 003 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> @ ICU MEDCL 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 N019685 003 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AP HOSPIRA 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 N019685 004 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> AP ICU MEDCL 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 N019685 004 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> @ HOSPIRA 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 N019685 001 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

>A> @ ICU MEDCL 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 N019685 001 Oct 17, 1988 Feb CAHN
00MG/100ML; 310MG/100ML

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

>D> AP HOSPIRA 33MG/100ML; 30MG/100ML; 860MG/100ML N018251 001 Feb CAHN

>A> AP ICU MEDCL 33MG/100ML; 30MG/100ML; 860MG/100ML N018251 001 Feb CAHN

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

>D> AT HOSPIRA 33MG/100ML; 30MG/100ML; 860MG/100ML N017635 001 Feb CAHN

>A> AT ICU MEDCL 33MG/100ML; 30MG/100ML; 860MG/100ML N017635 001 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AP HOSPIRA 20MG/100ML; 30MG/100ML; 600MG/100ML; N017641 001 Feb CAHN
310MG/100ML

>A> AP ICU MEDCL 20MG/100ML; 30MG/100ML; 600MG/100ML; N017641 001 Feb CAHN
310MG/100ML

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AT +! HOSPIRA 20MG/100ML; 30MG/100ML; 600MG/100ML; N019416 001 Jan 17, 1986 Feb CAHN
310MG/100ML

>A> AT +! ICU MEDCL 20MG/100ML; 30MG/100ML; 600MG/100ML; N019416 001 Jan 17, 1986 Feb CAHN
310MG/100ML

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>A> AB AMNEAL PHARMS 150MG A204741 001 Feb 28, 2017 Feb NEWA

>A> AB 500MG A204741 002 Feb 28, 2017 Feb NEWA

CARBAMAZEPINE

SOLUTION; IV (INFUSION)

CARNEXIV

+! LUNDBECK PHARMS LLC 200MG/20ML (10MG/ML) N206030 001 Oct 07, 2016 Jan CAHN

CARBOPLATIN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan	NEWA

CEFDINIR

CAPSULE; ORAL
OMNICEF

+ @	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan	CRLD
FOR SUSPENSION; ORAL							
OMNICEF							
+ @	ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan	CRLD
+ @		250MG/5ML	N050749	002	Jul 29, 2004	Jan	CRLD

CEFIXIME

FOR SUSPENSION; ORAL
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan	NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan	NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan	NEWA
SUPRAX							
AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan	CFTG

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan	CAHN

CEFPROZIL

TABLET; ORAL
CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan	CAHN
AB		500MG	A065340	002	May 24, 2007	Jan	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
CEFTRIAXONE SODIUM

AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan	NEWA
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER							
+ @	HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan	CRLD
+ @		EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan	CRLD
+ @		EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan	CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan	CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan	CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan	CAHN

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEPHAPIRIN SODIUM

@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan	CAHN
@		EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan	CAHN
@		EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan	CAHN

INJECTABLE; INJECTION
 CEPHAPIRIN SODIUM

@ EQ 20GM BASE/VIAL A062720 004 Jul 02, 1987 Jan CAHN

CHENODIOL

TABLET; ORAL
 CHENIX

>A> + @ LEADIANT BIOSCI INC 250MG N018513 002 Jul 28, 1983 Feb CAHN
 >D> + @ SIGMA TAU 250MG N018513 002 Jul 28, 1983 Feb CAHN

CHLORPROPAMIDE

TABLET; ORAL
 CHLORPROPAMIDE

@ ANI PHARMS INC 250MG A087353 001 Jan CAHN

CILOSTAZOL

TABLET; ORAL
 PLETAL

+ @ OTSUKA 50MG N020863 001 Jan 15, 1999 Jan CRLD
 + @ 100MG N020863 002 Jan 15, 1999 Jan CRLD

CIMETIDINE

TABLET; ORAL
 CIMETIDINE

@ CHARTWELL MOLECULES 200MG A074281 001 May 17, 1994 Jan CAHN
 @ 300MG A074281 002 May 17, 1994 Jan CAHN
 @ 400MG A074281 003 May 17, 1994 Jan CAHN
 @ 800MG A074329 001 May 17, 1994 Jan CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION
 CIPRO

>D> >D> AP +! BAYER HLTHCARE 400MG/40ML (10MG/ML) N019847 001 Dec 26, 1990 Feb DISC
 >A> + @ 400MG/40ML (10MG/ML) N019847 001 Dec 26, 1990 Feb DISC
 >D> AP +! 200MG/20ML (10MG/ML) N019847 002 Dec 26, 1990 Feb DISC
 >A> + @ 200MG/20ML (10MG/ML) N019847 002 Dec 26, 1990 Feb DISC
 >D> CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> AP +! BAYER HLTHCARE 200MG/100ML N019857 001 Dec 26, 1990 Feb DISC
 >A> + @ 200MG/100ML N019857 001 Dec 26, 1990 Feb DISC
 >D> AP +! 400MG/200ML N019857 002 Dec 26, 1990 Feb DISC
 >A> + @ 400MG/200ML N019857 002 Dec 26, 1990 Feb DISC

CIPROFLOXACIN

>D> AP CLARIS 200MG/20ML (10MG/ML) A078062 001 Apr 29, 2008 Feb CHRS
 >A> AP ! 200MG/20ML (10MG/ML) A078062 001 Apr 29, 2008 Feb CHRS
 >D> AP 400MG/40ML (10MG/ML) A078062 002 Apr 29, 2008 Feb CHRS
 >A> AP ! 400MG/40ML (10MG/ML) A078062 002 Apr 29, 2008 Feb CHRS
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> AP HOSPIRA 200MG/100ML A077753 001 Mar 18, 2008 Feb CHRS
 >A> AP ! 200MG/100ML A077753 001 Mar 18, 2008 Feb CHRS
 >D> AP 400MG/200ML A077753 002 Mar 18, 2008 Feb CHRS
 >A> AP ! 400MG/200ML A077753 002 Mar 18, 2008 Feb CHRS

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
 CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP JIANGSU HENGRUI MED EQ 2MG BASE/ML A204960 001 Jan 27, 2017 Jan NEWA

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL
 CITALOPRAM HYDROBROMIDE

AA AUROBINDO PHARMA LTD EQ 10MG BASE/5ML A077812 001 Aug 28, 2006 Jan CAHN

CLEMASTINE FUMARATE

TABLET; ORAL
 CLEMASTINE FUMARATE

>D> AB SANDOZ 2.68MG A073459 001 Oct 31, 1993 Feb DISC
 >A> @ 2.68MG A073459 001 Oct 31, 1993 Feb DISC
 >D> AB ! TEVA 2.68MG A073283 001 Jan 31, 1992 Feb CTEC
 >A> ! 2.68MG A073283 001 Jan 31, 1992 Feb CTEC

CLINDAMYCIN PHOSPHATE

	AEROSOL, FOAM;TOPICAL							
	EVOCLIN							
AT	+!	MYLAN PHARMS INC	1%		N050801	001	Oct 22, 2004	Jan CAHN
		INJECTABLE;INJECTION						
		CLINDAMYCIN PHOSPHATE						
AP		WEST-WARD PHARMS INT	EQ 150MG BASE/ML		A065206	001	Sep 24, 2004	Jan CAHN
		SOLUTION;TOPICAL						
		CLINDAMYCIN PHOSPHATE						
AT		FOUGERA PHARMS INC	EQ 1% BASE		A064159	001	Jun 05, 1997	Jan CAHN

CLOBAZAM

	SUSPENSION;ORAL							
	ONFI							
	+!	LUNDBECK PHARMS LLC	2.5MG/ML		N203993	001	Dec 14, 2012	Jan CAHN
		TABLET;ORAL						
		ONFI						
	@	LUNDBECK PHARMS LLC	5MG		N202067	001	Oct 21, 2011	Jan CAHN
	+		10MG		N202067	002	Oct 21, 2011	Jan CAHN
	+!		20MG		N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

	AEROSOL, FOAM;TOPICAL							
	OLUX							
AB1	+!	MYLAN PHARMS INC	0.05%		N021142	001	May 26, 2000	Jan CAHN
		OLUX E						
AB2	+!	MYLAN PHARMS INC	0.05%		N022013	001	Jan 12, 2007	Jan CAHN
		CREAM;TOPICAL						
		CLOBETASOL PROPIONATE						
AB1		FOUGERA PHARMS INC	0.05%		A074392	001	Sep 30, 1996	Jan CAHN
	@	MYLAN PHARMS INC	0.05%		A075338	001	Feb 09, 2001	Jan CAHN
		GEL;TOPICAL						
		CLOBETASOL PROPIONATE						
>A>	AB	TELIGENT PHARMA INC	0.05%		A208881	001	Mar 06, 2017	Feb NEWA
		OINTMENT;TOPICAL						
		CLOBETASOL PROPIONATE						
	@	MYLAN PHARMS INC	0.05%		A075057	001	Aug 12, 1998	Jan CAHN
		TEMOVATE						
	+	@	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CRLD
		SPRAY;TOPICAL						
		CLOBETASOL PROPIONATE						
>A>	AT	ZYDUS PHARMS USA INC	0.05%		A206378	001	Feb 16, 2017	Feb NEWA

CLOMIPRAMINE HYDROCHLORIDE

	CAPSULE;ORAL							
	CLOMIPRAMINE HYDROCHLORIDE							
>D>	@	SANDOZ	25MG		A074953	001	Jun 25, 1997	Feb CMFD
>A>	AB		25MG		A074953	001	Jun 25, 1997	Feb CMFD
>D>	@		50MG		A074953	002	Jun 25, 1997	Feb CMFD
>A>	AB		50MG		A074953	002	Jun 25, 1997	Feb CMFD
>D>	@		75MG		A074953	003	Jun 25, 1997	Feb CMFD
>A>	AB		75MG		A074953	003	Jun 25, 1997	Feb CMFD

CLONAZEPAM

	TABLET;ORAL							
	CLONAZEPAM							
>A>	AB	PRINSTON INC	0.5MG		A077856	001	Jun 28, 2006	Feb CAHN
>A>	AB		1MG		A077856	002	Jun 28, 2006	Feb CAHN
>A>	AB		2MG		A077856	003	Jun 28, 2006	Feb CAHN
>D>	AB	VINTAGE PHARMS	0.5MG		A077856	001	Jun 28, 2006	Feb CAHN
>D>	AB		1MG		A077856	002	Jun 28, 2006	Feb CAHN
>D>	AB		2MG		A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

	TABLET;ORAL							
	CLONIDINE HYDROCHLORIDE							
>A>	@	CHARTWELL MOLECULES	0.1MG		A071783	001	Apr 05, 1988	Feb CAHN
>A>	@		0.3MG		A071785	001	Apr 05, 1988	Feb CAHN
>D>	@	DAVA PHARMS INC	0.1MG		A071783	001	Apr 05, 1988	Feb CAHN
>D>	@		0.3MG		A071785	001	Apr 05, 1988	Feb CAHN

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
>A>	AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
>A>	AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN
>D>	AB	VINTAGE	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
>D>	AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
>D>	AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan NEWA
----	--	--------------------	--------------	---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ WEST-WARD PHARMS INT 30MG/5ML

N202245	001	Jun 30, 2011	Jan CAHN
---------	-----	--------------	----------

TABLET;ORAL

CODEINE SULFATE

AB	+	WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jan CAHN
AB	+	!	60MG	N022402	003	Jul 16, 2009	Jan CAHN

CROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

>D>	AN	BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN
>A>	AN		10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb CAHN
>A>	AB		10MG	A077797	002	Feb 28, 2007	Feb CAHN
>D>	AB	VINTAGE PHARMS	5MG	A077797	001	Feb 28, 2007	Feb CAHN
>D>	AB		10MG	A077797	002	Feb 28, 2007	Feb CAHN

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

+		WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan CAHN
+	!		50MG	N203856	002	Sep 16, 2013	Jan CAHN

INJECTABLE;INJECTION

CYTOXAN (LYOPHILIZED)

>D>		@ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb CRLD
>A>		+ @	500MG/VIAL	N012142	003		Feb CRLD
>D>		@	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
>A>		+ @	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
>D>		@	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD
>A>		+ @	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

PERIACTIN

+	@	MERCK	2MG/5ML	N013220	002		Jan CRLD
---	---	-------	---------	---------	-----	--	----------

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan NEWA
>D>	AA	COREPHARMA	4MG	A040537	001	Sep 30, 2003	Feb CAHN
>A>	AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

>A>		! LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN
>D>		! SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

>D>	AP	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS
>A>	AP	!	100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS
>D>	AP		200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS
>A>	AP	!	200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
AMPYRA

AB	+!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
		DALFAMPRIDINE						
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

>A>	+!	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb	NEWA
-----	----	----------------	---------------------------	---------	-----	--------------	-----	------

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

>A>	AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA
-----	----	-----------------	-----------	---------	-----	--------------	-----	------

DEFLAZACORTSUSPENSION; ORAL
EMFLAZA

>A>	+!	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
>A>		TABLET; ORAL						
>A>		EMFLAZA						
>A>	+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb	NEWA
>A>	+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
>A>	+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
>A>	+!		36MG	N208684	004	Feb 09, 2017	Feb	NEWA

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>D>	AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>D>	AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>D>	AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>D>	AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>D>	AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>D>	AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN
>A>	AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>A>	AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>A>	AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>A>	AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>A>	AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESOXIMETASONEGEL; TOPICAL
TOPICORT

+	@	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD
---	---	-------------------	-------	---------	-----	--------------	-----	------

SPRAY; TOPICAL
DESOXIMETASONE

AT		PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

TOPICORT

AT	+!	TARO	0.25%	N204141	001	Apr 11, 2013	Jan	CFTG
----	----	------	-------	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATESOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

>D>	AT	!	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb	CAHN
>A>	AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SUSPENSION/DROPS;OPHTHALMIC

MAXITROL									
>D>	AT	ALCON	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341	001	May 22, 1984	Feb	CAHN	
>A>	AT	SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341	001	May 22, 1984	Feb	CAHN	

DEXTROSE

INJECTABLE;INJECTION									
DEXTROSE 10% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	10GM/100ML	N018080	001		Feb	CAHN
>A>	AP	+	ICU MEDCL	10GM/100ML	N018080	001		Feb	CAHN
DEXTROSE 20% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN
>A>	AP	+	ICU MEDCL	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN
DEXTROSE 30% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN
>A>	AP	+	ICU MEDCL	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN
DEXTROSE 5% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	50MG/ML	N016367	002		Feb	CAHN
>A>	AP	+	ICU MEDCL	50MG/ML	N016367	002		Feb	CAHN
DEXTROSE 50% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN
>A>	AP	+	ICU MEDCL	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN
DEXTROSE 70% IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN
>A>	AP	+	ICU MEDCL	70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION									
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER									
>D>		HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001			Feb	CAHN
>A>		ICU MEDCL	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001			Feb	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION									
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER									
>D>		HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986	Feb	CAHN	
>A>		ICU MEDCL	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986	Feb	CAHN	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION									
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER									
>D>		HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;22MG/100ML;526MG/100ML;502MG/100ML	N017609	001			Feb	CAHN
>A>		ICU MEDCL	5GM/100ML;30MG/100ML;37MG/100ML;22MG/100ML;526MG/100ML;502MG/100ML	N017609	001			Feb	CAHN

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION									
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
>D>		HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN	
>D>			5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN	
>A>		ICU MEDCL	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN	
>A>			5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
>D>	AP		HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
>D>	AP			5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN
>A>	AP		ICU MEDCL	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
>A>	AP			5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
>D>		HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN	
>A>		ICU MEDCL	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
>D>	AP		HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>A>	AP ICU MEDCL 5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Feb	CAHN
>D>	5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN
>A>	ICU MEDCL 5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Feb	CAHN
>A>	5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
>D>	AP HOSPIRA 5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
>A>	ICU MEDCL 5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN
>A>	ICU MEDCL 5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb	CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN
>D>	5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN
>A>	ICU MEDCL 5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN
>A>	5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN
>D>	AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	+! HOSPIRA 5GM/100ML;225MG/100ML	N017606	001		Feb	CAHN
>A>	+! ICU MEDCL 5GM/100ML;225MG/100ML	N017606	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	+! HOSPIRA 5GM/100ML;300MG/100ML	N017799	001		Feb	CAHN
>A>	+! ICU MEDCL 5GM/100ML;300MG/100ML	N017799	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;450MG/100ML	N017607	001		Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;450MG/100ML	N017607	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP HOSPIRA 5GM/100ML;900MG/100ML	N017585	001		Feb	CAHN
>A>	AP ICU MEDCL 5GM/100ML;900MG/100ML	N017585	001		Feb	CAHN

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>D>	@ PAR PHARM 2MG	A070462	001	Feb 25, 1986	Feb	CAHN
>D>	@ 5MG	A070463	001	Feb 25, 1986	Feb	CAHN
>D>	@ 10MG	A070464	001	Feb 25, 1986	Feb	CAHN
>A>	@ VIRTUS PHARMS 2MG	A070462	001	Feb 25, 1986	Feb	CAHN
>A>	@ 5MG	A070463	001	Feb 25, 1986	Feb	CAHN
>A>	@ 10MG	A070464	001	Feb 25, 1986	Feb	CAHN

DICLOFENAC SODIUM

SOLUTION; TOPICAL

PENNSAID

>D>	AT +! NUVO RES INC 1.5%	N020947	001	Nov 04, 2009	Feb	DISC
>A>	+ @ 1.5%	N020947	001	Nov 04, 2009	Feb	DISC

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

>D>	AT ALCON PHARMS LTD 0.1%	A078031	001	Feb 06, 2008	Feb	CAHN
>A>	AT SANDOZ INC 0.1%	A078031	001	Feb 06, 2008	Feb	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

>A>	AP	LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb	NEWA
-----	----	---------------------	---------	---------	-----	--------------	-----	------

DIFLORASONE DIACETATE

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

>A>	AB	RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb	NEWA
-----	----	-----------------	-------	---------	-----	--------------	-----	------

DIGOXIN

ELIXIR;ORAL
DIGOXIN
+! WEST-WARD PHARMS INT 0.05MG/ML

N021648	001	Aug 26, 2004	Jan	CAHN
---------	-----	--------------	-----	------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

AP	WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan	CAHN
----	----------------------	--------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan	CAHN
----	----------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

>A>	@	CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992	Feb	CAHN
>A>	@		60MG	A074093	002	Nov 05, 1992	Feb	CAHN
>A>	@		90MG	A074093	003	Nov 05, 1992	Feb	CAHN
>A>	@		120MG	A074093	004	Nov 05, 1992	Feb	CAHN
>D>	@	DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992	Feb	CAHN
>D>	@		60MG	A074093	002	Nov 05, 1992	Feb	CAHN
>D>	@		90MG	A074093	003	Nov 05, 1992	Feb	CAHN
>D>	@		120MG	A074093	004	Nov 05, 1992	Feb	CAHN

DISULFIRAM

TABLET;ORAL
DISULFIRAM

AB	CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan	CAHN
AB		500MG	A091563	002	Dec 31, 2012	Jan	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

>A>	AB	PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb	CAHN
>A>	AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb	CAHN
>A>	AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb	CAHN
>D>	AB	VINTAGE	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb	CAHN
>D>	AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb	CAHN
>D>	AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb	CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>D>	AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb	CAHN
>D>	AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb	CAHN
>D>			140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb	CAHN
>A>	AP	ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb	CAHN
>A>	AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb	CAHN
>A>			140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb	CAHN
	AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan	NEWA
	AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan	NEWA
			200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan	NEWA
	+	HOSPIRA INC	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan	NEWA
	!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017	Jan	NEWA

INJECTABLE; INJECTION

DOCETAXEL

@	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
@		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
@		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
@		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

>A>	AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
>A>	AB		0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
>A>	AB		0.5MG	A207058	003	Jun 06, 2016	Feb CAHN
>D>	AB	TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
>D>	AB		0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
>D>	AB		0.5MG	A207058	003	Jun 06, 2016	Feb CAHN

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB			10MG;28MG	A208328	002	Jan 27, 2017	Jan NEWA
		NAMZARIC					
AB	+	FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+	!	10MG;28MG	N206439	002	Dec 23, 2014	Jan CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>D>	AT	ALCON PHARMS LTD	EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN
>A>	AT	SANDOZ INC	EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN

DOXEPIIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN
---	---	------------------	----	---------	-----	--------------	----------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

>A>	AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
>A>	AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

VIBRAMYCIN

+	@	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan CRLD
+	@		EQ 200MG BASE/VIAL	N050442	001		Jan CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

	@	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Jan CAHN
AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan CAHN

EPHEDRINE SULFATE

SOLUTION; IV (INFUSION)

CORPHEDRA

		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan NEWA
--	--	----------------------	-------------------	---------	-----	--------------	----------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>A>	@	BELMORA LLC	0.01MG/ML; 2%	A080504	004	Oct 19, 1983	Feb CAHN
>A>	@		0.02MG/ML; 2%	A080504	005	Oct 19, 1983	Feb CAHN
>D>	@	GRAHAM CHEM	0.01MG/ML; 2%	A080504	004	Oct 19, 1983	Feb CAHN
>D>	@		0.02MG/ML; 2%	A080504	005	Oct 19, 1983	Feb CAHN

EPLERENONE

	TABLET; ORAL							
	EPLERENONE							
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan	NEWA	
AB		50MG	A203896	002	Feb 02, 2017	Jan	NEWA	

ERYTHROMYCIN

	GEL; TOPICAL							
	E-GLADES							
	@ MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan	CAHN	
	ERYGEL							
AT	+! MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan	CAHN	
	SWAB; TOPICAL							
	ERYTHROMYCIN							
	@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan	CAHN	

ESOMEPRAZOLE SODIUM

	INJECTABLE; INTRAVENOUS							
	ESOMEPRAZOLE SODIUM							
>A>	AP DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA	

ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL							
	ESTRADIOL AND NORETHINDRONE ACETATE							
AB	MYLAN LABS LTD	0.5MG; 0.1MG	A207261	001	Feb 10, 2017	Jan	NEWA	
AB		1MG; 0.5MG	A207261	002	Feb 10, 2017	Jan	NEWA	

ESTROPIPATE

	TABLET; ORAL							
	ESTROPIPATE							
>D>	AB WATSON LABS	3MG	A081215	001	Sep 23, 1993	Feb	CAHN	
>A>	AB WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	Feb	CAHN	

>A>	<u>ETELCALCETIDE</u>							
>A>	SOLUTION; INTRAVENOUS							
>A>	PARSABIV							
>A>	+! KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb	NEWA	
>A>	+!	5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb	NEWA	
>A>	+!	10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb	NEWA	

ETHACRYNIC ACID

	TABLET; ORAL							
	ETHACRYNIC ACID							
>A>	AB WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb	NEWA	

ETHINYL ESTRADIOL; LEVONORGESTREL

	TABLET; ORAL-28							
	ELIFEMME							
>A>	AB LABS LEON FARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Feb	CAHN	
>D>	AB SANDOZ INC	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Feb	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET, CHEWABLE; ORAL							
	NEXESTA FE							
AB	AUROBINDO PHARMA LTD	0.035MG; 0.4MG	A207535	001	Feb 02, 2017	Jan	NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL							
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	MYLAN LABS LTD	0.0025MG; 0.5MG	A207260	001	Feb 02, 2017	Jan	NEWA	

ETODOLAC

	CAPSULE; ORAL							
	ETODOLAC							
	@ CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Jan	CAHN	
	@	300MG	A074842	002	Jul 17, 1997	Jan	CAHN	

TABLET;ORAL

ETODOLAC

@ CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan CAHN
-----------------------	-------	---------	-----	--------------	----------

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

>A>	AP	AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb NEWA
	AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan NEWA
	AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan CAHN

EXEMESTANE

TABLET;ORAL

EXEMESTANE

>A>	AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb NEWA
-----	----	------------------	------	---------	-----	--------------	----------

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan CHRS
		FAMVIR					
	+	@ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan DISC
	+	@	250MG	N020363	001	Apr 26, 1996	Jan DISC
	+	@	500MG	N020363	002	Jun 29, 1994	Jan DISC

FELBAMATE

TABLET;ORAL

FELBAMATE

>D>	AB	COREPHARMA	400MG	A202284	001	Nov 04, 2015	Feb CAHN
>D>	AB		600MG	A202284	002	Nov 04, 2015	Feb CAHN
>A>	AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb CAHN
>A>	AB		600MG	A202284	002	Nov 04, 2015	Feb CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

>A>	AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
>A>	AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB		AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB			200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

TABLET;ORAL

FLUCONAZOLE

>A>	AB	UNIQUE PHARM LABS	150MG	A076957	004	Feb 27, 2017	Feb NEWA
>A>	AB	ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
>A>	AB		100MG	A208963	002	Feb 16, 2017	Feb NEWA
>A>	AB		150MG	A208963	003	Feb 16, 2017	Feb NEWA
>A>	AB		200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>A>	AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
-----	----	-------------	--------------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUOCINOLONE ACETONIDE

	CREAM; TOPICAL							
	FLUOCINOLONE ACETONIDE							
AT	FOUGERA PHARMS INC	0.01%		A088170	001	Dec 16, 1982	Jan	CAHN
AT		0.025%		A088169	001	Dec 16, 1982	Jan	CAHN
	OINTMENT; TOPICAL							
	FLUOCINOLONE ACETONIDE							
AT	FOUGERA PHARMS INC	0.025%		A088168	001	Dec 16, 1982	Jan	CAHN
	SOLUTION; TOPICAL							
	FLUOCINOLONE ACETONIDE							
AT	FOUGERA PHARMS INC	0.01%		A088167	001	Dec 16, 1982	Jan	CAHN

FLUOCINONIDE

	CREAM; TOPICAL							
	FLUOCINONIDE							
AB1	FOUGERA PHARMS INC	0.05%		A073030	001	Oct 17, 1994	Jan	CAHN
	GEL; TOPICAL							
	FLUOCINONIDE							
AB	FOUGERA PHARMS INC	0.05%		A072933	001	Dec 30, 1994	Jan	CAHN

FLUOROURACIL

	INJECTABLE; INJECTION							
	FLUOROURACIL							
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)		N012209	001		Jan	CRLD

FLUOXETINE HYDROCHLORIDE

	SOLUTION; ORAL							
	FLUOXETINE HYDROCHLORIDE							
AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML		A079209	001	Mar 20, 2009	Jan	CAHN
	TABLET; ORAL							
	FLUOXETINE HYDROCHLORIDE							
	+! ALVOGEN	EQ 60MG BASE		N202133	001	Oct 06, 2011	Jan	CAHN

FLUPHENAZINE HYDROCHLORIDE

	CONCENTRATE; ORAL							
	FLUPHENAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC	5MG/ML		A073058	001	Aug 30, 1991	Jan	CAHN

FLURAZEPAM HYDROCHLORIDE

	CAPSULE; ORAL							
	FLURAZEPAM HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	15MG		A071717	002	Jul 31, 1991	Jan	CMS1

FLUTICASONE PROPIONATE

	POWDER; INHALATION							
	ARMONAIR RESPICLICK							
	+ TEVA PHARM	0.055MG/INH		N208798	001	Jan 27, 2017	Jan	NEWA
	+	0.113MG/INH		N208798	002	Jan 27, 2017	Jan	NEWA
	+!	0.232MG/INH		N208798	003	Jan 27, 2017	Jan	NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

	POWDER; INHALATION							
	AIRDUO RESPICLICK							
	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH		N208799	001	Jan 27, 2017	Jan	NEWA
	+	0.113MG/INH;EQ 0.014MG BASE/INH		N208799	002	Jan 27, 2017	Jan	NEWA
	+!	0.232MG/INH;EQ 0.014MG BASE/INH		N208799	003	Jan 27, 2017	Jan	NEWA

FORMOTEROL FUMARATE

	POWDER; INHALATION							
	FORADIL							
>D>	+! NOVARTIS	0.012MG/INH		N020831	001	Feb 16, 2001	Feb	DISC
>A>	+ @	0.012MG/INH		N020831	001	Feb 16, 2001	Feb	DISC

FOSINOPRIL SODIUM

	TABLET; ORAL							
	MONOPRIL							
	+ @ BRISTOL MYERS SQUIBB	10MG		N019915	002	May 16, 1991	Jan	CRLD
	+ @	20MG		N019915	003	May 16, 1991	Jan	CRLD
	+ @	40MG		N019915	004	Mar 28, 1995	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

AP	WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan	CAHN
AP		EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan	CAHN

FUROSEMIDE

TABLET; ORAL
FUROSEMIDE

>A>	AB	PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb	CAHN
>A>	AB		40MG	A076796	002	Mar 26, 2004	Feb	CAHN
>A>	AB		80MG	A076796	003	Mar 26, 2004	Feb	CAHN
>D>	AB	VINTAGE PHARMS	20MG	A076796	001	Mar 26, 2004	Feb	CAHN
>D>	AB		40MG	A076796	002	Mar 26, 2004	Feb	CAHN
>D>	AB		80MG	A076796	003	Mar 26, 2004	Feb	CAHN
	AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan	CAHN
	AB		40MG	N018823	002	Nov 10, 1983	Jan	CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan	CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan	CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan	CAHN

TABLET; ORAL
GABAPENTIN

>A>	AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb	NEWA
>A>	AB		800MG	A205807	002	Mar 10, 2017	Feb	NEWA

GANCICLOVIR

>A>	SOLUTION; IV (INFUSION)							
>A>	GANCICLOVIR							
>A>	+	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb	NEWA

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

>D>	AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Feb	CAHN
>A>	AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb	CAHN

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan	CHRS
	@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan	DISC

OINTMENT; TOPICAL
GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan	CAHN
----	--	--------------------	--------------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

>A>	AB	PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb	CAHN
>A>	AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN
>A>	AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN
>A>	AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN
>D>	AB	VINTAGE	1MG	A077370	001	Dec 23, 2005	Feb	CAHN
>D>	AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN
>D>	AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN
>D>	AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

+ @	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan	CRLD
+ @		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan	CRLD
+ @		5MG;500MG	N021460	003	Oct 21, 2002	Jan	CRLD

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>D>	AB2	COREPHARMA	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN
>D>	AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN
>D>	AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN
>A>	AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN
>A>	AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN
>A>	AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>D>	@	COREPHARMA	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb	CAHN
>D>	@		2.5MG;500MG	A076731	002	Nov 19, 2004	Feb	CAHN
>D>	@		5MG;500MG	A076731	003	Nov 19, 2004	Feb	CAHN
>A>	@	IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb	CAHN
>A>	@		2.5MG;500MG	A076731	002	Nov 19, 2004	Feb	CAHN
>A>	@		5MG;500MG	A076731	003	Nov 19, 2004	Feb	CAHN

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

>D>	AT	HOSPIRA	1.5GM/100ML	N018315	001		Feb	CAHN
>A>	AT	ICU MEDCL	1.5GM/100ML	N018315	001		Feb	CAHN

GLYCOPYRROLATE

POWDER; INHALATION

SEEBRI

+	!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan	CAHN
---	---	---------------------	-------------	---------	-----	--------------	-----	------

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+	!	SUNOVION PHARMS INC	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Jan	CAHN
---	---	---------------------	-------------------------	---------	-----	--------------	-----	------

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

+	!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan	CMFD
---	---	---------	------------------	---------	-----	--	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan	NEWA
AP		WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan	CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan	CAHN

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	@	FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb	CAHN
>D>	@	SUN PHARM INDS	20MG	A071177	001	Jan 07, 1988	Feb	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA
----	--	------------------	----------------	---------	-----	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>A>	AA	ABHAI LLC	1.5MG/5ML;5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA
>A>	AA	BIO-PHARM INC	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA
	AA	NOVEL LABS INC	1.5MG/5ML;5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA
	AA	PADDOCK LLC	1.5MG/5ML;5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA

TABLET;ORAL

TUSSIGON

>D>	AA	! KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Feb	CAHN
>A>	AA	!	1.5MG;5MG	A088508	001	Jul 30, 1985	Feb	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
>D>	AB	VINTAGE PHARMS	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
>A>	AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN
>D>	AB	VINTAGE PHARMS	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
>D>	AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

PRINZIDE

		+ @ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan	CRLD
		+ @	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan	CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan	CMS1
AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Jan	CMS1
AB			25MG;15MG	A202150	003	Mar 07, 2014	Jan	CMS1

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

		+ TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA
			30MG	N207975	002	Jan 17, 2017	Jan	NEWA
			45MG	N207975	003	Jan 17, 2017	Jan	NEWA
			60MG	N207975	004	Jan 17, 2017	Jan	NEWA
			90MG	N207975	005	Jan 17, 2017	Jan	NEWA

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT		! FOUGERA PHARMS INC	1%	A080693	003		Jan	CAHN
AT		!	2.5%	A089414	001	Dec 16, 1986	Jan	CAHN

OINTMENT;TOPICAL

HYDROCORTISONE

AT		! FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan	CAHN
----	--	----------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

CORTISPORIN

>D>		+! MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN
>A>		+!	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN
>A>	AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	!	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb CAHN
>A>	!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb CAHN

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb CAHN
>A>	AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

AP	+	!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
AP	+			2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
AP	+			4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN

DILAUDID-HP

AP	+	!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
		@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

HYDROXOCOBALAMIN

>A>	!	ACTAVIS LLC	1MG/ML	A085998	001		Feb CAHN
>D>	!	WATSON LABS	1MG/ML	A085998	001		Feb CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VISTARIL

	+	@	PFIZER	25MG/ML	N011111	001		Jan CRLD
	+	@		50MG/ML	N011111	002		Jan CRLD

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan CMS1
	@		25MG	A087871	003	Dec 20, 1982	Jan CMS1
>A>	AB	PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb CAHN
>A>	AB		25MG	A040574	001	May 27, 2005	Feb CAHN
>A>	AB		50MG	A040580	001	May 27, 2005	Feb CAHN
>D>	AB	VINTAGE PHARMS	10MG	A040579	001	May 27, 2005	Feb CAHN
>D>	AB		25MG	A040574	001	May 27, 2005	Feb CAHN
>D>	AB		50MG	A040580	001	May 27, 2005	Feb CAHN

IBUPROFEN

SUSPENSION;ORAL

MOTRIN

	+	@	MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan CRLD
--	---	---	-----------------	-----------	---------	-----	--------------	----------

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

	+	!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jan CAHN
--	---	---	---------------------	---------------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

>A>	@	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb CAHN
>A>	@		50MG	N018829	001	Aug 06, 1984	Feb CAHN
>D>	@	VINTAGE	25MG	N018829	002	Aug 06, 1984	Feb CAHN
>D>	@		50MG	N018829	001	Aug 06, 1984	Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

>D>	AB	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb DISC
>A>	@		75MG	A202572	001	Dec 09, 2013	Feb DISC

IOPAMIDOLINJECTABLE; INJECTION
SCANLUX-300

>D>	AP	MYLAN IRELAND LTD	61%	A 090394	001	Jun 18, 2010	Feb CAHN
	AP		61%	A 090394	001	Jun 18, 2010	Jan CAHN
>A>	AP	SANOCHEMIA CORP USA	61%	A 090394	001	Jun 18, 2010	Feb CAHN
		SCANLUX-370					
>D>	AP	MYLAN IRELAND LTD	76%	A 090394	002	Jun 18, 2010	Feb CAHN
	AP		76%	A 090394	002	Jun 18, 2010	Jan CAHN
>A>	AP	SANOCHEMIA CORP USA	76%	A 090394	002	Jun 18, 2010	Feb CAHN

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A 078753	001	Dec 24, 2008	Jan CAHN
AP			100MG/5ML (20MG/ML)	A 078753	002	Dec 24, 2008	Jan CAHN

ISOSORBIDE DINITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE

>D>		@ COREPHARMA	40MG	A 040723	001	Mar 17, 2008	Feb CAHN
>A>		@ IMPAX LABS INC	40MG	A 040723	001	Mar 17, 2008	Feb CAHN

ITRACONAZOLECAPSULE; ORAL
ITRACONAZOLE

>A>	AB	JUBILANT GENERICS	100MG	A 203445	001	Feb 23, 2017	Feb NEWA
-----	----	-------------------	-------	----------	-----	--------------	----------

KANAMYCIN SULFATEINJECTABLE; INJECTION
KANAMYCIN

		@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A 062324	001		Jan CAHN
		@	EQ 500MG BASE/2ML	A 062324	002		Jan CAHN
		@	EQ 1GM BASE/3ML	A 062324	003		Jan CAHN

KETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA

AT	+!	MYLAN PHARMS INC	2%	N 021738	001	Jun 12, 2007	Jan CAHN
----	----	------------------	----	----------	-----	--------------	----------

KETOPROFENCAPSULE; ORAL
KETOPROFEN

>D>		DORADO PHARMA	25MG	A 074014	001	Jan 29, 1993	Feb CAHN
>D>	AB		50MG	A 074014	002	Jan 29, 1993	Feb CAHN
>D>	AB		75MG	A 074014	003	Jan 29, 1993	Feb CAHN
>A>		HERITAGE PHARMS INC	25MG	A 074014	001	Jan 29, 1993	Feb CAHN
>A>	AB		50MG	A 074014	002	Jan 29, 1993	Feb CAHN
>A>	AB		75MG	A 074014	003	Jan 29, 1993	Feb CAHN

KETOROLAC TROMETHAMINESOLUTION/DROPS; OPHTHALMIC
KETOROLAC TROMETHAMINE

>D>	AT	ALCON PHARMS LTD	0.5%	A 076583	001	Nov 05, 2009	Feb CAHN
>A>	AT	SANDOZ INC	0.5%	A 076583	001	Nov 05, 2009	Feb CAHN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

>A>	AP	SAGENT AGILA	5MG/ML	A 079134	001	Feb 03, 2010	Feb CAHN
>D>	AP	SAGENT STRIDES	5MG/ML	A 079134	001	Feb 03, 2010	Feb CAHN

LAMIVUDINETABLET; ORAL
LAMIVUDINE

>A>	AB	CIPLA LTD	150MG	A 077221	001	Mar 03, 2017	Feb NEWA
>A>	AB		300MG	A 077221	002	Mar 03, 2017	Feb NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan	CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan	CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan	CAHN

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>D>	AT	ALCON RES	0.005%	A091449	001	Mar 22, 2011	Feb	CAHN
>A>	AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan	NEWA
----	----------------------	---------------	---------	-----	--------------	-----	------

LEVETIRACETAM

SOLUTION;ORAL
LEVETIRACETAM

AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan	CAHN
----	----------------------	----------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

>D>	AB	PAR PHARM	500MG	A091291	001	Sep 12, 2011	Feb	CAHN
>D>	AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN
>A>	AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN
>A>	AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN
>D>	AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN
>D>	AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN
>A>	AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb	CAHN
>A>	AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

>D>	AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Feb	DISC
>A>		@	0.25%	A074851	001	Oct 28, 1996	Feb	DISC
>D>	AT	ALCON RES LTD	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN
>A>	AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN

LEVOCARNITINE

TABLET;ORAL
LEVOCARNITINE

>D>	AB	COREPHARMA	330MG	A076858	001	Sep 20, 2004	Feb	CAHN
>A>	AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb	CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD
+	@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD
+	@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

>D>	AT	WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN
>A>	AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)
LEVOLEUCOVORIN CALCIUM

AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan	NEWA
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan	NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

>A>		@ BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb	CAHN
>D>		@ GRAHAM CHEM	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb	CAHN

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

>A>	AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb NEWA
	AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan CAHN
		XYLOCAINE					
		+ @ ASTRAZENECA	5%	N008048	001		Jan CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

>A>		@ BELMORA LLC	2%	A080504	001		Feb CAHN
>D>		@ GRAHAM CHEM	2%	A080504	001		Feb CAHN

LINACLOTIDE

CAPSULE;ORAL
LINZESS

		+ FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan NEWA
--	--	-------------------	-------	---------	-----	--------------	----------

LINEZOLID

SOLUTION;IV (INFUSION)
LINEZOLID

>A>	AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb NEWA
>A>	AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb NEWA

TABLET;ORAL
LINEZOLID

>A>	AB	ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb NEWA
-----	----	----------------------	-------	---------	-----	--------------	----------

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL
VYVANSE

		+ SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan NEWA
			20MG	N208510	002	Jan 28, 2017	Jan NEWA
			30MG	N208510	003	Jan 28, 2017	Jan NEWA
			40MG	N208510	004	Jan 28, 2017	Jan NEWA
			50MG	N208510	005	Jan 28, 2017	Jan NEWA
			60MG	N208510	006	Jan 28, 2017	Jan NEWA

LISINOPRIL

TABLET;ORAL
LISINOPRIL

>A>	AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
>A>	AB		5MG	A075743	002	Jul 01, 2002	Feb CAHN
>A>	AB		10MG	A075743	003	Jul 01, 2002	Feb CAHN
>A>	AB		20MG	A075743	004	Jul 01, 2002	Feb CAHN
>A>	AB		30MG	A075743	005	Jul 01, 2002	Feb CAHN
>A>	AB		40MG	A075743	006	Jul 01, 2002	Feb CAHN
>D>	AB	VINTAGE	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
>D>	AB		5MG	A075743	002	Jul 01, 2002	Feb CAHN
>D>	AB		10MG	A075743	003	Jul 01, 2002	Feb CAHN
>D>	AB		20MG	A075743	004	Jul 01, 2002	Feb CAHN
>D>	AB		30MG	A075743	005	Jul 01, 2002	Feb CAHN
>D>	AB		40MG	A075743	006	Jul 01, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL
LITHIUM CARBONATE

AB		MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
AB			300MG	A076243	001	Jun 27, 2002	Jan CAHN
AB			600MG	A078763	001	Apr 15, 2008	Jan CAHN
AB		+ WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB			300MG	N017812	001		Jan CAHN
AB		+!	600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET;ORAL
LITHIUM CARBONATE

AB		+! WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
----	--	-------------------------	-------	---------	-----	--------------	----------

LITHIUM CITRATE

SYRUP;ORAL
LITHIUM CITRATE

AA +! WEST-WARD PHARMS INT EQ 300MG CARBONATE/5ML N018421 001 Jan CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION
NORMOSOL-R IN PLASTIC CONTAINER

>D> HOSPIRA 30MG/100ML;37MG/100ML;222MG/100ML; N017586 001 Feb CAHN
526MG/100ML;502MG/100ML
>A> ICU MEDCL 30MG/100ML;37MG/100ML;222MG/100ML; N017586 001 Feb CAHN
526MG/100ML;502MG/100ML

SOLUTION;IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

>D> HOSPIRA 30MG/100ML;37MG/100ML;222MG/100ML; N017637 002 Jul 08, 1982 Feb CAHN
526MG/100ML;502MG/100ML
>A> ICU MEDCL 30MG/100ML;37MG/100ML;222MG/100ML; N017637 002 Jul 08, 1982 Feb CAHN
526MG/100ML;502MG/100ML

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE
NOVEL LABS INC 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT
SUPREP BOWEL PREP KIT

>A> AA N022372 001 Feb 23, 2017 Feb NEWA
>D> +! BRAINTREE LABS 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT N022372 001 Aug 05, 2010 Feb CFTG
>A> AA +! N022372 001 Aug 05, 2010 Feb CFTG

MANNITOL

INJECTABLE;INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

>D> AP HOSPIRA 10GM/100ML N019603 002 Jan 08, 1987 Feb CAHN
>A> AP ICU MEDCL 10GM/100ML N019603 002 Jan 08, 1987 Feb CAHN

MANNITOL 15% IN PLASTIC CONTAINER

>D> AP HOSPIRA 15GM/100ML N019603 003 Jan 08, 1990 Feb CAHN
>A> AP ICU MEDCL 15GM/100ML N019603 003 Jan 08, 1990 Feb CAHN

MANNITOL 20% IN PLASTIC CONTAINER

>D> AP HOSPIRA 20GM/100ML N019603 004 Jan 08, 1990 Feb CAHN
>A> AP ICU MEDCL 20GM/100ML N019603 004 Jan 08, 1990 Feb CAHN

MANNITOL 5% IN PLASTIC CONTAINER

>D> AP HOSPIRA 5GM/100ML N019603 001 Jan 08, 1987 Feb CAHN
>A> AP ICU MEDCL 5GM/100ML N019603 001 Jan 08, 1987 Feb CAHN

MANNITOL; SORBITOL

SOLUTION;IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER

>D> HOSPIRA 540MG/100ML;2.7GM/100ML N018316 001 Feb CAHN
>A> ICU MEDCL 540MG/100ML;2.7GM/100ML N018316 001 Feb CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION
MEDROXYPROGESTERONE ACETATE
TEVA PHARMS USA 150MG/ML

AB A076553 001 Jul 28, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL
MEGACE
BRISTOL MYERS SQUIBB 40MG/ML

>D> AB +! N020264 001 Sep 10, 1993 Feb DISC
>A> + @ N020264 001 Sep 10, 1993 Feb DISC
WEST-WARD PHARMS INT 40MG/ML
>D> AB A075997 001 Feb 15, 2002 Feb CHRS
>A> AB ! A075997 001 Feb 15, 2002 Feb CHRS

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION
MELPHALAN HYDROCHLORIDE
SAGENT PHARMS EQ 50MG BASE/VIAL

>A> AP A201379 001 Feb 28, 2017 Feb NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/ML	A 080445	001		Jan	CAHN
AP		25MG/ML	A 080455	007		Jan	CAHN
AP		50MG/ML	A 080445	002		Jan	CAHN
AP		50MG/ML	A 080455	008		Jan	CAHN
AP		75MG/ML	A 080445	003		Jan	CAHN
AP		75MG/ML	A 080455	009		Jan	CAHN
AP		100MG/ML	A 080445	004		Jan	CAHN
AP		100MG/ML	A 080455	010		Jan	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPIVACAINE HYDROCHLORIDE

>A>	@ BELMORA LLC	3%	A 083559	001		Feb	CAHN
>D>	@ GRAHAM CHEM	3%	A 083559	001		Feb	CAHN

METAXALONE

TABLET; ORAL
METAXALONE

>D>	COREPHARMA	400MG	A 040486	001	Feb 27, 2015	Feb	CAHN
>A>	IMPAX LABS INC	400MG	A 040486	001	Feb 27, 2015	Feb	CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>A>	AB1	INTELLIPHARMACEUTICS	500MG	A 202306	001	Feb 23, 2017	Feb	NEWA
>A>	AB		750MG	A 202306	002	Feb 23, 2017	Feb	NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL
DOLOPHINE HYDROCHLORIDE

	@ WEST-WARD PHARMS INT	10MG/30ML	N 006134	004		Jan	CAHN
--	------------------------	-----------	----------	-----	--	-----	------

TABLET; ORAL
DOLOPHINE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	5MG	N 006134	002	Jan	CAHN
AA	+		10MG	N 006134	010	Jan	CAHN

TABLET, FOR SUSPENSION; ORAL
METHADONE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	40MG	N 017058	001	Jan	CAHN
----	---	----------------------	------	----------	-----	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL
METHENAMINE HIPPURATE

>D>	AB	COREPHARMA	1GM	A 076411	001	Jun 20, 2003	Feb	CAHN
>A>	AB	IMPAX LABS INC	1GM	A 076411	001	Jun 20, 2003	Feb	CAHN

METHIMAZOLE

TABLET; ORAL
TAPAZOLE

>D>	AB	KING PHARMS	5MG	A 040320	001	Mar 31, 2000	Feb	CAHN
>D>	AB		10MG	A 040320	002	Mar 31, 2000	Feb	CAHN
>A>	AB	KING PHARMS LLC	5MG	A 040320	001	Mar 31, 2000	Feb	CAHN
>A>	AB		10MG	A 040320	002	Mar 31, 2000	Feb	CAHN

METHOCARBAMOL

SOLUTION; IM-IV
METHOCARBAMOL

AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A 208116	001	Jan 19, 2017	Jan	NEWA
----	--------------------	---------------------	----------	-----	--------------	-----	------

TABLET; ORAL
METHOCARBAMOL

AA	ATLAS PHARMS LLC	500MG	A 203550	001	Feb 08, 2017	Jan	NEWA
AA		750MG	A 203550	002	Feb 08, 2017	Jan	NEWA

METHOTREXATE SODIUM

TABLET; ORAL

METHOTREXATE SODIUM

AB ZYDUS PHARMS USA INC EQ 2.5MG BASE A207812 001 Jan 13, 2017 Jan NEWA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

! LUITPOLD 50MG/ML A071279 001 Oct 02, 1987 Jan CTEC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> AB2 COREPHARMA 10MG A205105 001 Jul 28, 2016 Feb CAHN
 >D> AB2 20MG A205105 002 Jul 28, 2016 Feb CAHN
 >D> AB2 30MG A205105 003 Jul 28, 2016 Feb CAHN
 >D> AB2 40MG A205105 004 Jul 28, 2016 Feb CAHN
 >D> AB2 50MG A205105 005 Jul 28, 2016 Feb CAHN
 >D> AB2 60MG A205105 006 Jul 28, 2016 Feb CAHN
 >A> AB2 IMPAX LABS INC 10MG A205105 001 Jul 28, 2016 Feb CAHN
 >A> AB2 20MG A205105 002 Jul 28, 2016 Feb CAHN
 >A> AB2 30MG A205105 003 Jul 28, 2016 Feb CAHN
 >A> AB2 40MG A205105 004 Jul 28, 2016 Feb CAHN
 >A> AB2 50MG A205105 005 Jul 28, 2016 Feb CAHN
 >A> AB2 60MG A205105 006 Jul 28, 2016 Feb CAHN
 >D> AB1 MAYNE PHARMA 60MG A078458 004 Jun 23, 2016 Feb CHRS
 >A> ! 60MG A078458 004 Jun 23, 2016 Feb CHRS
 RITALIN LA
 >D> AB1 +! NOVARTIS 60MG N021284 005 Oct 27, 2014 Feb DISC
 >A> + @ 60MG N021284 005 Oct 27, 2014 Feb DISC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> AB COREPHARMA 5MG A091159 001 Mar 12, 2014 Feb CAHN
 >D> AB 10MG A091159 002 Mar 12, 2014 Feb CAHN
 >D> AB 20MG A091159 003 Mar 12, 2014 Feb CAHN
 >A> AB IMPAX LABS INC 5MG A091159 001 Mar 12, 2014 Feb CAHN
 >A> AB 10MG A091159 002 Mar 12, 2014 Feb CAHN
 >A> AB 20MG A091159 003 Mar 12, 2014 Feb CAHN
 >A> AB NOSTRUM LABS INC 5MG A207587 001 Mar 03, 2017 Feb NEWA
 >A> AB 10MG A207587 002 Mar 03, 2017 Feb NEWA
 >A> AB 20MG A207587 003 Mar 03, 2017 Feb NEWA

TABLET, CHEWABLE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB NOSTRUM LABS INC 2.5MG A204954 001 Jan 26, 2017 Jan NEWA
 AB 5MG A204954 002 Jan 26, 2017 Jan NEWA
 AB 10MG A204954 003 Jan 26, 2017 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

RITALIN-SR

>D> AB NOVARTIS 20MG N018029 001 Mar 30, 1982 Feb CRLD
 >A> AB + 20MG N018029 001 Mar 30, 1982 Feb CRLD

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

@ HOSPIRA INC EQ 40MG BASE/VIAL A040793 001 Nov 25, 2008 Jan DISC
 @ EQ 125MG BASE/VIAL A040827 001 Nov 25, 2008 Jan DISC

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

>D> AT ALCON RES LTD 0.3% A075720 001 Aug 06, 2001 Feb CAHN
 >A> AT SANDOZ INC 0.3% A075720 001 Aug 06, 2001 Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D> AB NORTHSTAR HLTHCARE EQ 5MG BASE A078374 001 Nov 30, 2007 Feb DISC
 >A> @ EQ 5MG BASE A078374 001 Nov 30, 2007 Feb DISC
 >D> AB EQ 10MG BASE A078374 002 Nov 30, 2007 Feb DISC
 >A> @ EQ 10MG BASE A078374 002 Nov 30, 2007 Feb DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN
----	--	----------------------	--------	---------	-----	--------------	----------

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

>A>	AB		TARO	1%	A204651	001	Mar 14, 2017	Feb NEWA
-----	----	--	------	----	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

	+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
--	---	---	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

>D>		@	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
>A>		+	@	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
>D>		@		5MG	N019815	002	Sep 06, 1996	Feb CRLD
>A>		+	@	5MG	N019815	002	Sep 06, 1996	Feb CRLD
>D>		@		10MG	N019815	003	Mar 20, 2002	Feb CRLD
>A>		+	@	10MG	N019815	003	Mar 20, 2002	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL
SAVELLA

>A>	AB	+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
>A>	AB	+		25MG	N022256	002	Jan 14, 2009	Feb CAHN
>A>	AB	+	!	50MG	N022256	003	Jan 14, 2009	Feb CAHN
>A>	AB	+		100MG	N022256	004	Jan 14, 2009	Feb CAHN
>D>	AB	+	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
>D>	AB	+		25MG	N022256	002	Jan 14, 2009	Feb CAHN
>D>	AB	+	!	50MG	N022256	003	Jan 14, 2009	Feb CAHN
>D>	AB	+		100MG	N022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN	
AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN	
AP		WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN	
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN	
			PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
		+	@ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
		+	@	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
		+	@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
		+	@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ

>D>	+	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
>A>	+	!	25MG	N202611	001	Jun 28, 2012	Feb	CHRS

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB			30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB			45MG	A077376	004	Feb 28, 2006	Jan	CAHN

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP		WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN
AP			5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP			20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN
		MUTAMYCIN						
	+	@ BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
	+	@	20MG/VIAL	N050450	002		Jan	CRLD

MORPHINE SULFATE

SOLUTION;ORAL
MORPHINE SULFATE

AA	+	WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan	CAHN
AA	+		20MG/5ML	N022195	002	Mar 17, 2008	Jan	CAHN
AA	+	!	100MG/5ML	N022195	003	Jan 25, 2010	Jan	CAHN

TABLET;ORAL

MORPHINE SULFATE

	+	WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan	CAHN
	+	!	30MG	N022207	002	Mar 17, 2008	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

	+	EGALET	15MG	N208603	001	Jan 09, 2017	Jan	NEWA
	+		30MG	N208603	002	Jan 09, 2017	Jan	NEWA
	+		60MG	N208603	003	Jan 09, 2017	Jan	NEWA

MORPHABOND ER

	+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan	CTNA
	+		30MG	N206544	002	Oct 02, 2015	Jan	CTNA
	+		60MG	N206544	003	Oct 02, 2015	Jan	CTNA
	+	!	100MG	N206544	004	Oct 02, 2015	Jan	CTNA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE

AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan	NEWA
----	--	----------------	---------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

>A>	AP		AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb	NEWA
-----	----	--	-----------	------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE

		@ WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986	Jan	CAHN	
		@	0.4MG/ML	A070496	001	Sep 24, 1986	Jan	CAHN	
		NALOXONE HYDROCHLORIDE							
>A>	AP		AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb	NEWA
>A>	AP			0.4MG/ML	A208872	001	Mar 14, 2017	Feb	NEWA

SPRAY, METERED;NASAL

NARCAN

	+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan	NEWA
--	---	-------	-----------	---------	-----	--------------	-----	------

NAPROXEN

	TABLET;ORAL								
	NAPROXEN								
AB	AUROBINDO PHARMA LTD	250MG		A200429	001	Nov 08, 2011	Jan	CAHN	
AB		375MG		A200429	002	Nov 08, 2011	Jan	CAHN	
AB		500MG		A200429	003	Nov 08, 2011	Jan	CAHN	

NATAMYCIN

SUSPENSION;OPHTHALMIC
NATACYN

+!	NOVARTIS PHARMS CORP	5%		N050514	001		Jan	CAHN	
----	----------------------	----	--	---------	-----	--	-----	------	--

NELFINAVIR MESYLATE

POWDER;ORAL
VIRACEPT

@	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL		N020778	001	Mar 14, 1997	Jan	CAHN	
---	----------------	-----------------------	--	---------	-----	--------------	-----	------	--

TABLET;ORAL
VIRACEPT

+!	AGOURON PHARMS	EQ 250MG BASE		N020779	001	Mar 14, 1997	Jan	CAHN	
----	----------------	---------------	--	---------	-----	--------------	-----	------	--

+!		EQ 625MG BASE		N021503	001	Apr 30, 2003	Jan	CAHN	
----	--	---------------	--	---------	-----	--------------	-----	------	--

>D> NEOMYCIN SULFATE

SOLUTION;ORAL

>D>	NEO-FRADIN								
>D>	!	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002	Feb	DISC	

>A>	@		EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002	Feb	DISC	
-----	---	--	--------------------	---------	-----	--------------	-----	------	--

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

>A>	AB	AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Feb	NEWA	
-----	----	----------------------	-------	---------	-----	--------------	-----	------	--

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009	Jan	CAHN	
----	----------------------	----------------------	--	---------	-----	--------------	-----	------	--

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>A>		EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Feb	NEWA	
-----	--	----------------------	-----------------------	---------	-----	--------------	-----	------	--

>A>			40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Feb	NEWA	
-----	--	--	-----------------------	---------	-----	--------------	-----	------	--

NITROGLYCERIN

OINTMENT;TRANSDERMAL
NITROGLYCERIN

!	FOUGERA PHARMS INC	2%		A087355	001	Jul 08, 1988	Jan	CAHN	
---	--------------------	----	--	---------	-----	--------------	-----	------	--

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML		A040462	001	Oct 31, 2003	Jan	CAHN	
----	----------------------	----------------	--	---------	-----	--------------	-----	------	--

NYSTATIN

SUSPENSION;ORAL
NYSTATIN

AA	FOUGERA PHARMS INC	100,000 UNITS/ML		A062517	001	Jun 07, 1984	Jan	CAHN	
----	--------------------	------------------	--	---------	-----	--------------	-----	------	--

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
MYCOLOG-II

@	MYLAN PHARMS INC	100,000 UNITS/GM;0.1%		A062606	001	May 15, 1985	Jan	CAHN	
---	------------------	-----------------------	--	---------	-----	--------------	-----	------	--

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%		A062599	001	Oct 08, 1985	Jan	CAHN	
----	--------------------	-----------------------	--	---------	-----	--------------	-----	------	--

OINTMENT;TOPICAL
MYCOLOG-II

@	MYLAN PHARMS INC	100,000 UNITS/GM;0.1%		A060572	001	Jun 28, 1985	Jan	CAHN	
---	------------------	-----------------------	--	---------	-----	--------------	-----	------	--

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%		A207741	001	Jan 31, 2017	Jan	NEWA	
----	--------------------	-----------------------	--	---------	-----	--------------	-----	------	--

AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%		A062602	001	Oct 09, 1985	Jan	CAHN	
----	--------------------	-----------------------	--	---------	-----	--------------	-----	------	--

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

>D>	AT	ALCON PHARMS LTD	0.3%	A076231	001	May 14, 2004	Feb	CAHN
>A>	AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN

SOLUTION/DROPS;OTIC
OFLOXACIN

>D>	AT	ALCON PHARMS LTD	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN
>A>	AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN

OLOPATADINE HYDROCHLORIDESPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB		PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan	NEWA
----	--	----------------	---------------	---------	-----	--------------	-----	------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB		AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan	CAHN
AB			20MG	A203270	002	Aug 19, 2015	Jan	CAHN
AB			40MG	A203270	003	Aug 19, 2015	Jan	CAHN

OMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan	CTEC
AB			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan	CTEC
AB		PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan	CMFD
AB			40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan	CMFD
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan	CTEC
AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan	CTEC

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN
			ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN

OSELTAMIVIR PHOSPHATECAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

>A>	AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA
>A>	AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA
>A>	AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA

OXALIPLATININJECTABLE;IV (INFUSION)
ELOXATIN

+	@	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD
			OXALIPLATIN					
AP		CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA
AP		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA
AP			200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA
AP		GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan	NEWA
AP	!	QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan	CTEC

OXAZEPAMTABLET;ORAL
OXAZEPAM

@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jan	CAHN
---	----------------	------	---------	-----	--------------	-----	------

OXYBUTYNIN

>D> GEL, METERED;TRANSDERMAL
 >D> GELNIQUE 3%
 >D> +! ALLERGAN SALES LLC 3% N202513 001 Dec 07, 2011 Feb DISC
 >A> + @ 3% N202513 001 Dec 07, 2011 Feb DISC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL
 DITROPAN
 + @ ORTHO MCNEIL JANSSEN 5MG/5ML N018211 001 Jan CRLD

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL
 RHOFADE
 +! ALLERGAN INC 1% N208552 001 Jan 18, 2017 Jan NEWA

PARICALCITOL

SOLUTION;INTRAVENOUS
 PARICALCITOL
 >A> AP AMNEAL PHARMS CO 0.002MG/ML (0.002MG/ML) A206699 001 Mar 09, 2017 Feb NEWA
 >A> AP 0.005MG/ML (0.005MG/ML) A206699 002 Mar 09, 2017 Feb NEWA
 >A> AP 0.01MG/2ML (0.005MG/ML) A206699 003 Mar 09, 2017 Feb NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 PAROXETINE HYDROCHLORIDE
 AB LUPIN LTD EQ 12.5MG BASE A204134 001 Jan 20, 2017 Jan NEWA
 AB EQ 25MG BASE A204134 002 Jan 20, 2017 Jan NEWA
 AB EQ 37.5MG BASE A204134 003 Jan 20, 2017 Jan NEWA

PENCICLOVIR

CREAM;TOPICAL
 DENAVIR
 +! MYLAN PHARMS INC 1% N020629 001 Sep 24, 1996 Jan CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
 TRENAL
 + @ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CRLD

PERMETHRIN

CREAM;TOPICAL
 ELIMITE
 AB +! MYLAN PHARMS INC 5% N019855 001 Aug 25, 1989 Jan CAHN

PERPHENAZINE

TABLET;ORAL
 PERPHENAZINE
 @ ANI PHARMS INC 4MG A089708 001 Sep 10, 1987 Jan CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
 PHENOXYBENZAMINE HYDROCHLORIDE
 AB PAR PHARM INC 10MG A204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL
 PHENTERMINE HYDROCHLORIDE
 >A> AA PRINSTON INC 37.5MG A040377 001 Jan 04, 2002 Feb CAHN
 >D> AA VINTAGE PHARMS 37.5MG A040377 001 Jan 04, 2002 Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)
 VAZCULEP
 + AVADEL LEGACY 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Jan CAHN
 + 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Jan CAHN
 +! 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Jan CAHN

PHENYTOIN

TABLET, CHEWABLE;ORAL
DILANTIN

>A>	AB	!	PFIZER	50MG	A084427	001		Feb	CAHN
>D>	AB	!	PFIZER PHARMS	50MG	A084427	001		Feb	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL
DILANTIN

>D>	AB	!	PARKE DAVIS	30MG EXTENDED	A084349	001		Feb	CAHN
>D>	AB	!		100MG EXTENDED	A084349	002		Feb	CAHN
>A>	AB	!	PARKE-DAVIS	30MG EXTENDED	A084349	001		Feb	CAHN
>A>	AB	!		100MG EXTENDED	A084349	002		Feb	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

AP			APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	NEWA
AP				EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	NEWA
AP				EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	NEWA
AP				EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	NEWA

PIRFENIDONE

TABLET;ORAL
ESBRIET

+			GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	NEWA
+	@			534MG	N208780	002	Jan 11, 2017	Jan	DISC
+	!			801MG	N208780	003	Jan 11, 2017	Jan	NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL
PITAVASTATIN CALCIUM

AB			ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA
AB				EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA
AB				EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA
AB			SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA
AB				EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA
AB				EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA

PLECANATIDE

TABLET;ORAL
TRULANCE

+	!		SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan	NEWA
---	---	--	----------------	-----	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>A>	AA		BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Feb	NEWA
-----	----	--	---------------------	--	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

>D>	AT		ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CAHN
>A>	AT		SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CAHN

POTASSIUM CHLORIDE

INJECTABLE;INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
>D>	AP	+		745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN
>A>	AP	+	ICU MEDCL	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
>A>	AP	+		745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
>D>	AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN
>A>	AP	+	ICU MEDCL	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
>A>	AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN
>A>	AP	+	ICU MEDCL	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER									
>D>	AP	+	HOSPIRA	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb	CAHN
>A>	AP	+	ICU MEDCL	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb	CAHN
>A>	AP		ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb	CAHN
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
>D>	AP		HOSPIRA	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb	CAHN
>A>	AP		ICU MEDCL	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb	CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
>D>	AP		HOSPIRA	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb	CAHN
>A>	AP		ICU MEDCL	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb	CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

>D>	AB		COREPHARMA	5MEQ	A077440	001	Jun 09, 2006	Feb	CAHN
>D>	AB			10MEQ	A077440	002	Jun 09, 2006	Feb	CAHN
>A>	AB		IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb	CAHN
>A>	AB			10MEQ	A077440	002	Jun 09, 2006	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

			@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan	DISC
			@		0.25MG	A091254	002	Nov 30, 2010	Jan	DISC
			@		0.5MG	A091254	003	Nov 30, 2010	Jan	DISC
			@		0.75MG	A091254	004	Nov 30, 2010	Jan	DISC
			@		1MG	A091254	005	Nov 30, 2010	Jan	DISC
			@		1.5MG	A091254	006	Nov 30, 2010	Jan	DISC
>D>	AB			SANDOZ	0.125MG	A090190	001	Jul 06, 2010	Feb	DISC
>A>			@		0.125MG	A090190	001	Jul 06, 2010	Feb	DISC
>D>	AB				0.25MG	A090190	002	Jul 06, 2010	Feb	DISC
>A>			@		0.25MG	A090190	002	Jul 06, 2010	Feb	DISC
>D>	AB				0.5MG	A090190	003	Jul 06, 2010	Feb	DISC
>A>			@		0.5MG	A090190	003	Jul 06, 2010	Feb	DISC
>D>	AB				0.75MG	A090190	006	Oct 08, 2010	Feb	DISC
>A>			@		0.75MG	A090190	006	Oct 08, 2010	Feb	DISC
>D>	AB				1MG	A090190	004	Jul 06, 2010	Feb	DISC
>A>			@		1MG	A090190	004	Jul 06, 2010	Feb	DISC
>D>	AB				1.5MG	A090190	005	Jul 06, 2010	Feb	DISC
>A>			@		1.5MG	A090190	005	Jul 06, 2010	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB				MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan	NEWA
----	--	--	--	---------------------	--------	---------	-----	--------------	-----	------

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB				AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan	NEWA
AB					20MG	A203367	002	Feb 02, 2017	Jan	NEWA
AB					40MG	A203367	003	Feb 02, 2017	Jan	NEWA
AB					80MG	A203367	004	Feb 02, 2017	Jan	NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

>D>	AT			ALCON PHARMS LTD	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb	CAHN
>D>	AT	!		BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CAHN
>A>	AT	!			EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CAHN
>A>	AT			SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb	CAHN

PREDNISONE

TABLET; ORAL
 PREDNISONE
 AB MYLAN PHARMS INC 5MG A 080292 001 Jan CAHN
 AB 10MG A 088832 001 Dec 04, 1985 Jan CAHN
 AB 20MG A 083677 001 Jan CAHN

PROBENECID

TABLET; ORAL
 BENEMID
 + @ MERCK 500MG N 007898 004 Jan CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 PROCAINAMIDE HYDROCHLORIDE
 @ WEST-WARD PHARMS INT 100MG/ML A 089029 001 Apr 17, 1986 Jan CAHN

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL
 MATULANE
 >A> +! LEADIANT BIOSCI INC EQ 50MG BASE N 016785 001 Feb CAHN
 >D> +! SIGMA TAU EQ 50MG BASE N 016785 001 Feb CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
 COMPAZINE
 >D> @ GLAXOSMITHKLINE EQ 5MG BASE/ML N 010742 002 Feb CRLD
 >A> + @ EQ 5MG BASE/ML N 010742 002 Feb CRLD
 PROCHLORPERAZINE EDISYLATE
 @ WEST-WARD PHARMS INT EQ 5MG BASE/ML A 089523 001 May 03, 1988 Jan CAHN
 AP EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Jan CAHN

PROGESTERONE

CAPSULE; ORAL
 PROGESTERONE
 >A> AB DR REDDYS LABS INC 100MG A 208801 001 Feb 28, 2017 Feb NEWA
 >A> AB 200MG A 208801 002 Feb 28, 2017 Feb NEWA
 INJECTABLE; INJECTION
 PROGESTERONE
 >A> AO +! ACTAVIS LABS UT INC 50MG/ML N 017362 002 Feb CAHN
 >D> AO +! ALLERGAN SALES LLC 50MG/ML N 017362 002 Feb CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
 PHENERGAN
 + @ MYLAN PHARMS INC 50MG N 011689 001 Jan CAHN
 TABLET; ORAL
 PROMETHAZINE HYDROCHLORIDE
 >A> AB PRINSTON INC 12.5MG A 040622 001 Jul 18, 2006 Feb CAHN
 >A> AB 25MG A 040622 002 Jul 18, 2006 Feb CAHN
 >A> AB 50MG A 040622 003 Jul 18, 2006 Feb CAHN
 >D> AB VINTAGE PHARMS 12.5MG A 040622 001 Jul 18, 2006 Feb CAHN
 >D> AB 25MG A 040622 002 Jul 18, 2006 Feb CAHN
 >D> AB 50MG A 040622 003 Jul 18, 2006 Feb CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 LARGON
 @ WEST-WARD PHARMS INT 20MG/ML N 012382 002 Jan CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 PROPRANOLOL HYDROCHLORIDE
 >D> BX UPSHER SMITH 60MG A 078311 001 Mar 06, 2009 Feb DISC
 >A> @ 60MG A 078311 001 Mar 06, 2009 Feb DISC
 >D> BX 80MG A 078311 002 Mar 06, 2009 Feb DISC
 >A> @ 80MG A 078311 002 Mar 06, 2009 Feb DISC
 >D> BX 120MG A 078311 003 Mar 06, 2009 Feb DISC
 >A> @ 120MG A 078311 003 Mar 06, 2009 Feb DISC
 >D> BX 160MG A 078311 004 Mar 06, 2009 Feb DISC
 >A> @ 160MG A 078311 004 Mar 06, 2009 Feb DISC

TABLET;ORAL
INDERAL

+ @ WYETH PHARMS INC 40MG N016418 002 Jan CRLD

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

@ WEST-WARD PHARMS INT 10MG/ML A089475 001 Nov 05, 1986 Jan CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

>D> @ COREPHARMA 60MG A040457 001 Dec 26, 2002 Feb CAHN
>A> @ IMPAX LABS INC 60MG A040457 001 Dec 26, 2002 Feb CAHN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

>A> AB AUROBINDO PHARMA LTD 20MG A205761 001 Feb 17, 2017 Feb NEWA
AB KREMERS URBAN PHARMS 20MG A090678 001 Nov 08, 2013 Jan CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC

AP +! TELIGENT PHARMA INC EQ 25MG BASE/ML N019090 001 Oct 19, 1984 Jan CAHN
SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA AUROBINDO PHARMA LTD EQ 15MG BASE/ML A090623 001 Jul 28, 2010 Jan CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANEXA

>D> AB + GILEAD 500MG N021526 002 Jan 27, 2006 Feb CTEC
>A> + 500MG N021526 002 Jan 27, 2006 Feb CTEC
>D> AB +! 1GM N021526 001 Feb 12, 2007 Feb CTEC
>A> +! 1GM N021526 001 Feb 12, 2007 Feb CTEC
>D> RANOLAZINE
>D> AB LUPIN LTD 500MG A201046 001 Jul 29, 2013 Feb DISC
>A> @ 500MG A201046 001 Jul 29, 2013 Feb DISC
>D> AB 1GM A201046 002 Jul 29, 2013 Feb DISC
>A> @ 1GM A201046 002 Jul 29, 2013 Feb DISC

REPAGLINIDE

TABLET;ORAL
PRANDIN

>A> AB + GEMINI LABS LLC 0.5MG N020741 001 Dec 22, 1997 Feb CAHN
>A> AB + 1MG N020741 002 Dec 22, 1997 Feb CAHN
>A> AB +! 2MG N020741 003 Dec 22, 1997 Feb CAHN
>D> AB + NOVO NORDISK INC 0.5MG N020741 001 Dec 22, 1997 Feb CAHN
>D> AB + 1MG N020741 002 Dec 22, 1997 Feb CAHN
>D> AB +! 2MG N020741 003 Dec 22, 1997 Feb CAHN

RIBAVIRIN

CAPSULE;ORAL
RIBASPHERE

AB KADMON PHARMS LLC 200MG A076203 001 Apr 06, 2004 Jan CAHN

TABLET;ORAL
RIBAVIRIN

AB KADMON PHARMS LLC 200MG A077456 001 Dec 05, 2005 Jan CAHN
AB 400MG A077456 002 Dec 05, 2005 Jan CAHN
AB ! 600MG A077456 003 Dec 05, 2005 Jan CAHN

RIFAMPIN

INJECTABLE; INJECTION
RIFAMPIN

>D> AP WATSON PHARMS INC 600MG/VIAL A206736 001 Jan 19, 2016 Feb CAHN
>A> AP WATSON PHARMS TEVA 600MG/VIAL A206736 001 Jan 19, 2016 Feb CAHN
AP WEST-WARD PHARMS INT 600MG/VIAL A064217 001 Oct 29, 1999 Jan CAHN

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

>D>	@ COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb CAHN
>A>	@ IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb CAHN

RISPERIDONE

TABLET;ORAL

RISPERIDONE

>A>	AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
>A>	AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
>A>	AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
>A>	AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
>A>	AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
>A>	AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN
>D>	AB	VINTAGE	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
>D>	AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
>D>	AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
>D>	AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
>D>	AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
>D>	AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

>A>	AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb NEWA
>A>	AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA	
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA	
>A>	AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb NEWA
>A>	AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A>	AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb NEWA
>A>	AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
>A>	AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ CHARTWELL MOLECULES 5MG

A074565 001 Aug 02, 1996 Jan CAHN

@ 5MG

A074641 001 Aug 02, 1996 Jan CAHN

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN

+ TCG FLUENT PHARMA 20MG/5ML

N206679 001 Apr 21, 2016 Jan CAHN

+! 40MG/5ML

N206679 002 Apr 21, 2016 Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
 SUMATRIPTAN SUCCINATE
 AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG
 BASE/ML) A079123 001 Feb 06, 2009 Jan CAHN
 SYSTEM;IONTOPHORESIS
 ZECUITY
 + @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
 TAMSULOSIN HYDROCHLORIDE
 AB MACLEODS PHARMS LTD 0.4MG A204645 001 Jan 20, 2017 Jan NEWA

TAZAROTENE

AEROSOL, FOAM;TOPICAL
 FABIOR
 +! MAYNE PHARMA 0.1% N202428 001 May 11, 2012 Jan CAHN

>A> TELOTRIPTAT ETIPRATE

>A> TABLET;ORAL
 >A> XERMELO
 >A> +! LEXICON PHARMS INC EQ 250MG BASE N208794 001 Feb 28, 2017 Feb NEWA

TEMAZEPAM

CAPSULE;ORAL
 TEMAZEPAM
 >A> AB PRINSTON INC 7.5MG A201781 001 Jun 04, 2015 Feb CAHN
 >A> AB 15MG A201781 002 Jun 04, 2015 Feb CAHN
 >A> AB 22.5MG A201781 003 Jun 04, 2015 Feb CAHN
 >A> AB 30MG A201781 004 Jun 04, 2015 Feb CAHN
 >D> AB VINTAGE PHARMS 7.5MG A201781 001 Jun 04, 2015 Feb CAHN
 >D> AB 15MG A201781 002 Jun 04, 2015 Feb CAHN
 >D> AB 22.5MG A201781 003 Jun 04, 2015 Feb CAHN
 >D> AB 30MG A201781 004 Jun 04, 2015 Feb CAHN

TEMOZOLOMIDE

CAPSULE;ORAL
 TEMOZOLOMIDE
 >A> AB ACCORD HLTHCARE 5MG A201528 001 Feb 27, 2017 Feb NEWA
 >A> AB 20MG A201528 002 Feb 27, 2017 Feb NEWA
 >A> AB 100MG A201528 003 Feb 27, 2017 Feb NEWA
 >A> AB 140MG A201528 004 Feb 27, 2017 Feb NEWA
 >A> AB 180MG A201528 005 Feb 27, 2017 Feb NEWA
 >A> AB 250MG A201528 006 Feb 27, 2017 Feb NEWA

TERBUTALINE SULFATE

TABLET;ORAL
 BRETHINE
 >A> + @ ANI PHARMS INC 2.5MG N017849 001 Feb CAHN
 >A> + @ 5MG N017849 002 Feb CAHN
 >D> + @ PHARMACARE LTD 2.5MG N017849 001 Feb CAHN
 >D> + @ 5MG N017849 002 Feb CAHN
 TERBUTALINE SULFATE
 ! LANNETT 5MG A077152 002 Mar 25, 2005 Jan CHRS

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL
 AXIRON
 >D> +! ELI LILLY AND CO 30MG/1.5ML ACTUATION N022504 001 Nov 23, 2010 Feb CFTG
 >A> AT +! 30MG/1.5ML ACTUATION N022504 001 Nov 23, 2010 Feb CFTG
 TESTOSTERONE
 >A> AT PERRIGO ISRAEL 30MG/1.5ML ACTUATION A204255 001 Feb 28, 2017 Feb NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION
 TESTOSTERONE CYPIONATE
 >D> AO WATSON LABS 200MG/ML A086030 001 Feb CAHN
 >A> AO WATSON PHARMS INC 200MG/ML A086030 001 Feb CAHN
 AO WEST-WARD PHARMS INT 100MG/ML A090387 001 Jul 15, 2010 Jan CAHN
 AO 200MG/ML A090387 002 Jul 15, 2010 Jan CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

>D>	AO	WATSON LABS	200MG/ML	A 085598	001		Feb	CAHN
>A>	AO	WATSON PHARMS INC	200MG/ML	A 085598	001		Feb	CAHN

TETRABENAZINE

TABLET; ORAL
TETRABENAZINE

AB		APICORE US	12.5MG	A 207682	001	Jan 31, 2017	Jan	NEWA
AB			25MG	A 207682	002	Jan 31, 2017	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

AB	+	HERITAGE PHARMA	250MG	N 050278	003		Jan	CAHN
AB	+	!	500MG	N 050278	001		Jan	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE
@ WEST-WARD PHARMS INT

100MG/ML	A 080575	001		Jan	CAHN
----------	----------	-----	--	-----	------

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HYDROCHLORIDE
@ ANI PHARMS INC

30MG/ML	A 089602	001	Nov 09, 1987	Jan	CAHN
---------	----------	-----	--------------	-----	------

THIOTEPA

POWDER; IV (INFUSION)
TEPADINA

+	!	ADIENNE SA	15MG/VIAL	N 208264	001	Jan 26, 2017	Jan	NEWA
+	!		100MG/VIAL	N 208264	002	Jan 26, 2017	Jan	NEWA

TICAGRELOR

TABLET; ORAL
BRILINTA

+		ASTRAZENECA PHARMS	60MG	N 022433	002	Sep 03, 2015	Jan	CAHN
+	!		90MG	N 022433	001	Jul 20, 2011	Jan	CAHN

TIGECYCLINE

>D> INJECTABLE; IV (INFUSION)
>D> TIGECYCLINE

>D>	AP	SANDOZ INC	50MG/VIAL	A 091620	001	May 27, 2015	Feb	CDFR
-----	----	------------	-----------	----------	-----	--------------	-----	------

>D>	AP	+	!	PF PRISM CV	50MG/VIAL	N 021821	001	Jun 15, 2005	Feb	CDFR
-----	----	---	---	-------------	-----------	----------	-----	--------------	-----	------

>A>	AP			SANDOZ INC	50MG/VIAL	A 091620	001	May 27, 2015	Feb	CDFR
-----	----	--	--	------------	-----------	----------	-----	--------------	-----	------

>A>	AP	+	!	PF PRISM CV	50MG/VIAL	N 021821	001	Jun 15, 2005	Feb	CDFR
-----	----	---	---	-------------	-----------	----------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

>D>	AB	ALCON RES LTD	EQ 0.25% BASE	N 020963	001	Oct 21, 1998	Feb	CAHN
-----	----	---------------	---------------	----------	-----	--------------	-----	------

>D>	AB		EQ 0.5% BASE	N 020963	002	Oct 21, 1998	Feb	CAHN
-----	----	--	--------------	----------	-----	--------------	-----	------

>A>	AB	SANDOZ INC	EQ 0.25% BASE	N 020963	001	Oct 21, 1998	Feb	CAHN
-----	----	------------	---------------	----------	-----	--------------	-----	------

>A>	AB		EQ 0.5% BASE	N 020963	002	Oct 21, 1998	Feb	CAHN
-----	----	--	--------------	----------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

>D>	AT	!	ALCON RES LTD	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Feb	CAHN
-----	----	---	---------------	---------------	----------	-----	--------------	-----	------

AT	!		EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Jan	CHRS
----	---	--	---------------	----------	-----	--------------	-----	------

>D>	AT1	!		EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Feb	CAHN
-----	-----	---	--	--------------	----------	-----	--------------	-----	------

AT1	!		EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Jan	CHRS
-----	---	--	--------------	----------	-----	--------------	-----	------

>A>	AT	!	SANDOZ INC	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Feb	CAHN
-----	----	---	------------	---------------	----------	-----	--------------	-----	------

>A>	AT1	!		EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Feb	CAHN
-----	-----	---	--	--------------	----------	-----	--------------	-----	------

TIMOPTIC

+	@	ATON	EQ 0.25% BASE	N 018086	001		Jan	DISC
---	---	------	---------------	----------	-----	--	-----	------

+	@		EQ 0.5% BASE	N 018086	002		Jan	DISC
---	---	--	--------------	----------	-----	--	-----	------

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE

AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan	CTEC
AB		500MG	A202489	002	Oct 09, 2013	Jan	CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

>A>	AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb	NEWA
>A>	AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb	NEWA
>A>	AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb	NEWA
>A>	AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb	NEWA
>A>	AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb	NEWA

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan	NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan	NEWA

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC
TOBREX

>D>	AT	ALCON	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN
>A>	AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOREMIFENE CITRATE

TABLET;ORAL
FARESTON

+!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan	CAHN
----	-------------	--------------	---------	-----	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

>A>	AP	AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan	NEWA	

TRETINOIN

CREAM;TOPICAL
TRETINOIN

>D>	!	ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Feb	DISC
>A>	@		0.0375%	A090098	001	Mar 22, 2010	Feb	DISC
>D>			0.075%	A202209	001	Oct 11, 2012	Feb	DISC
>A>	@		0.075%	A202209	001	Oct 11, 2012	Feb	DISC
>D>	AB2	SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN
>A>	AB2	ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA
AT		0.1%	A208763	002	Feb 01, 2017	Jan	NEWA
AT		0.5%	A208763	003	Feb 01, 2017	Jan	NEWA
AT	+ MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN
AT	+	0.1%	N011601	006		Jan	CAHN

OINTMENT;TOPICAL
KENALOG

AT	MYLAN PHARMS INC	0.025%	N011600	003		Jan	CAHN
AT		0.1%	N011600	001		Jan	CAHN

TRIAMCINOLONE ACETONIDE

>A>	AT	TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb	NEWA
-----	----	---------------------	------	---------	-----	--------------	-----	------

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA
----	------------------	------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
---	----------------	---------------	---------	-----	--------------	-----	------

TRIFLURIDINESOLUTION/DROPS;OPHTHALMIC
TRIFLURIDINE

>D>	AT	ALCON PHARMS LTD	1%	A074311	001	Oct 06, 1995	Feb CAHN
>A>	AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb CAHN
VIOPTIC							
>D>	AT	+! MONARCH PHARMS	1%	N018299	001		Feb CAHN
>A>	AT	+!	1%	N018299	001		Feb CAHN

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC
MYDRIACYL

>D>	AT	! ALCON	0.5%	A084305	001		Feb CAHN
>A>	AT	! SANDOZ INC	0.5%	A084305	001		Feb CAHN

ULIPRISTAL ACETATETABLET;ORAL
ELLA

AB	+!	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan CFTG
LOGILIA							
AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan NEWA

URSODIOLCAPSULE;ORAL
URSODIOL

>D>	AB	COREPHARMA	300MG	A077895	001	Jul 27, 2006	Feb CAHN
>A>	AB	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	Feb CAHN

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

>D>	AA	ALPHARMA	250MG/5ML	A075782	001	Dec 22, 2000	Feb CAHN
>A>	AA	VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb CAHN

VALSARTANTABLET;ORAL
VALSARTAN

>D>	AB	MYLAN LABS LTD	40MG	A090866	001	Jan 05, 2015	Feb CAHN
>D>	AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
>D>	AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
>D>	AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN
>A>	AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb CAHN
>A>	AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
>A>	AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
>A>	AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN

VECURONIUM BROMIDEINJECTABLE;INJECTION
VECURONIUM BROMIDE

AP		WEST-WARD PHARMS INT	10MG/VIAL	A075549	001	Jun 13, 2000	Jan CAHN
AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan CAHN

VENLAFAXINE HYDROCHLORIDETABLET;ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
>A>	AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
>A>	AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
>A>	AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
>A>	AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN
>D>	AB	VINTAGE	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
>D>	AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
>D>	AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
>D>	AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
>D>	AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CALAN SR

+ @	PFIZER	180MG	N019152	002	Dec 15, 1989	Jan	CRLD
	COVERA-HS						
@	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan	DISC
@		240MG	N020552	002	Feb 26, 1996	Jan	DISC

VIGABATRIN

FOR SOLUTION;ORAL
SABRIL

+!	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN
	TABLET;ORAL						
	SABRIL						
+!	LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN
----	----------------------	-----------------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb	NEWA
>A>	AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb	NEWA
>A>	AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb	NEWA
>A>	AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
----	----------------	-------------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

>A>	AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
>A>	AB		5MG	A207867	002	Feb 27, 2017	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

>A>	+	SANOFI-AVENTIS US	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb CAHN
>D>	+	UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb CAHN
	+		2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

>A>	+	SANOFI-AVENTIS US	5MG	N209089	001	Jan 31, 2017	Feb CAHN
>D>	+	UCB INC	5MG	N209089	001	Jan 31, 2017	Feb CAHN
	+		5MG	N209089	001	Jan 31, 2017	Jan NEWA

LOPERAMIDE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

	+	@ J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Jan DISC
--	---	------------------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

	+	@ J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Jan DISC
--	---	------------------------	-----------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	!	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002	Jan CHRS
--	---	---------	-----------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

>A>		WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Feb NEWA
-----	--	-----------------	----	---------	-----	--------------	----------

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

LNK INTL INC

EQ 200MG BASE

				A204872	001	Jan 23, 2017	Jan NEWA
--	--	--	--	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA

EQ 150MG BASE

				A200536	001	Jun 28, 2011	Jan CAHN
--	--	--	--	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL

0.055MG/SPRAY

				A078104	002	Nov 14, 2014	Jan CAHN
--	--	--	--	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2017

NO FEBRUARY 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001					M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	>A> 8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	>A> 8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	>A> 8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	>A> 9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	>A> 9549926	Oct 14, 2031	U-1965			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					>A> NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					>A> NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					>A> NP	Jan 21, 2018
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	>A> 5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	>A> 5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	>A> 5763476	Jun 09, 2020	DP U-1961			
	>A> 5763476	Jun 09, 2020	DP U-1962			
	>A> 5763476	Jun 09, 2020	DP U-1963			
	>A> 5763476*PED	Dec 09, 2020				
	>A> 7741358	Apr 06, 2026	DS DP U-1064			
	>A> 7741358	Apr 06, 2026	DS DP U-1960			
	>A> 7741358	Apr 06, 2026	DS DP U-1961			
	>A> 7741358	Apr 06, 2026	DS DP U-1962			
	>A> 7741358	Apr 06, 2026	DS DP U-1963			
	>A> 7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	>A> 5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	>A> 5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	>A> 5763476	Jun 09, 2020	DP U-1961			
	>A> 5763476	Jun 09, 2020	DP U-1962			
	>A> 5763476	Jun 09, 2020	DP U-1963			
	>A> 5763476*PED	Dec 09, 2020				
	>A> 7741358	Apr 06, 2026	DS DP U-1064			
	>A> 7741358	Apr 06, 2026	DS DP U-1960			
	>A> 7741358	Apr 06, 2026	DS DP U-1961			
	>A> 7741358	Apr 06, 2026	DS DP U-1962			
	>A> 7741358	Apr 06, 2026	DS DP U-1963			
	>A> 7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	>A> 5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	>A> 5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	>A> 5763476*PED	Dec 09, 2020				
	>A> 7741358	Apr 06, 2026	DS DP U-1893			
	>A> 7741358	Apr 06, 2026	DS DP U-1966			
	>A> 7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	>A> 9284314	Jun 15, 2032	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 9572796	Jan 28, 2031	DP U-1971			
	>A> 9572796	Jan 28, 2031	DP U-1972			
	>A> 9572797	Jan 28, 2031	U-1971			
	>A> 9572797	Jan 28, 2031	U-1972			
	>A> 9572887	Mar 15, 2033	U-1971			
	>A> 9572887	Mar 15, 2033	U-1972			
	>A> 9579384	Mar 15, 2033	U-1971			
	>A> 9579384	Mar 15, 2033	U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	>A> 9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	6123924*PED	Mar 26, 2018			PED	Jul 27, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-1073			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-1073			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	>A> 8528545	Oct 16, 2028	DP			
	>A> 8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-1073			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	6123924*PED	Mar 26, 2018				
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-1073			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-1118			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-1073			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-1118			
	8461211*PED	Mar 09, 2019				
	>A> 8528545	Oct 16, 2028	DP			
	>A> 8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-1073			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	6123924*PED	Mar 26, 2018				
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-1073			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-1118			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-1073			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-1118			
	8461211*PED	Mar 09, 2019				
	>A> 8528545	Oct 16, 2028	DP			
	>A> 8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-1073			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001				>A> M-197		Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002				>A> M-197		Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001				>A> M-197		Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002				>A> M-197		Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003				>A> M-197		Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004				>A> M-197		Feb 01, 2020
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	>A> 9493582	Feb 27, 2033	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	>A> 9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	>A> 9493582	Feb 27, 2033	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001					NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	>A> 9555029	Aug 22, 2033	U-1020			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		>A> NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001					>A> M-175	Apr 05, 2019
					>A> NC	Feb 27, 2020
					>A> NCE	Jan 08, 2019
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					>A> PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					>A> PC	Aug 28, 2017
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	>A> 9539335	Oct 17, 2027	U-1614			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	>A> 9545414	Jun 13, 2026	DP U-750			
	>A> 9545414	Jun 13, 2026	DP U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	>A> 9566272	Jan 03, 2028	U-1969			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	>A> 8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	>A> 8772325	Mar 14, 2025	U-1709			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001				>A> NCE		Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002				>A> NCE		Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003				>A> NCE		Feb 07, 2022
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
>A>	9572779	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
>A>	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
>A>	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
>A>	9572803	Sep 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
>A>	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
>A>	9572803	Sep 13, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382	Aug 18, 2033	U-1456		I-741	Jan 18, 2020
	9540382	Aug 18, 2033	U-1650		ODE	Jan 18, 2024
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	>A> 9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 7973038	Nov 08, 2026	U-1973			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	>A> 7973038	Nov 08, 2026	U-1973			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	>A> 7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	>A> 7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	>A> 7704947	Jan 28, 2024	DS DP			
	>A> 7745409	Jan 28, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	>A> 8080526	Jan 28, 2024	DS DP			
	>A> 8110553	Jan 28, 2024		U-1516		
	>A> 8933030	Feb 17, 2031	DP	U-1516		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 9555001	Mar 06, 2033	DP	U-1967		
	>A> 9555001	Mar 06, 2033	DP	U-1968		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 9555001	Mar 06, 2033	DP	U-1967		
	>A> 9555001	Mar 06, 2033	DP	U-1968		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	>A> 7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023		DP	M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP	U-727		
	>A> 7659254	Feb 24, 2023		U-727		
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023		U-727		
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7713936	Feb 24, 2023		U-727		
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7723305	Feb 24, 2023	DP	U-727		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	>A> 7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023		DP	M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP	U-727		
	>A> 7659254	Feb 24, 2023		U-727		
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023		U-727		
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7713936	Feb 24, 2023		U-727		
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7723305	Feb 24, 2023	DP	U-727		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	>A> 7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023		DP	M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP	U-727		
	>A> 7659254	Feb 24, 2023		U-727		
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023		U-727		
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP	U-727		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7718619	Feb 24, 2023	DP U-727			
	>A> 7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP U-727			
	>A> 7659254	Feb 24, 2023	U-727			
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7671030	Feb 24, 2023	DP U-727			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-727			
	>A> 7678770	Feb 24, 2023	U-727			
	>A> 7678771	Feb 24, 2023	DP U-727			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP U-727			
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7718619	Feb 24, 2023	DP U-727			
	>A> 7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP U-727			
	>A> 7659254	Feb 24, 2023	U-727			
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7671030	Feb 24, 2023	DP U-727			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-727			
	>A> 7678770	Feb 24, 2023	U-727			
	>A> 7678771	Feb 24, 2023	DP U-727			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP U-727			
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7718619	Feb 24, 2023	DP U-727			
	>A> 7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	>A> 7655630	Feb 24, 2023	DS DP			
	>A> 7659253	Feb 24, 2023	DS DP U-727			
	>A> 7659254	Feb 24, 2023	U-727			
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7671030	Feb 24, 2023	DP U-727			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-727			
	>A> 7678770	Feb 24, 2023	U-727			
	>A> 7678771	Feb 24, 2023	DP U-727			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP U-727			
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7718619	Feb 24, 2023	DP U-727			
	>A> 7723305	Feb 24, 2023	DP U-727			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	>A> 9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
					NPP	Jan 27, 2020
					PED	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	>A> 9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	>A> 9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	>A> 9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	>A> 9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430 6667314 7368460 7576097	Dec 01, 2019 Aug 06, 2021 Nov 25, 2022 May 25, 2021	DS DP U-824 DS DP U-824 U-824 DS		NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430 6667314 7368460 7576097	Dec 01, 2019 Aug 06, 2021 Nov 25, 2022 May 25, 2021	DS DP U-824 DS DP U-824 U-824 DS		NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	>A> 9493582	Feb 27, 2033	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	>A> 9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	>A> 9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	>A> 9549899	Jul 01, 2033	DP U-1556			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	>A> 9561177	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	>A> 9480644	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018		U-1942		
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931	001				>A> I-743	Jul 24, 2018
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	001	>A> 9492443	May 26, 2024	DP		
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	002	9492443	May 26, 2024	DP		
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552	001	7812049	May 02, 2028	U-1959	NP	Jan 18, 2020
		8420688	Aug 02, 2024	U-1959		
		8883838	Dec 01, 2031	DP		
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	>A> 9511046	Jan 12, 2034	U-1434		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	>A> 9439854	Jan 30, 2024	DP		
		>A> 9439854*PED	Jul 30, 2024			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	>A> 9439854	Jan 30, 2024	DP		
		>A> 9439854*PED	Jul 30, 2024			
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	>A> 9545457	Jan 13, 2019	U-665		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	001	>A> 9566271	Jan 15, 2024	U-1974		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	001				NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	002				NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	003				NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PLECANATIDE - TRULANCE</u>						
N 208745	001	7041786	Mar 25, 2023	DS	NCE	Jan 19, 2022
		7799897	Jun 09, 2022	DS		
		8637451	Mar 28, 2022	U-1964		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	001	9493470	Dec 12, 2033	DS DP U-1700		
		9493470	Dec 12, 2033	DS DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	002	9493470	Dec 12, 2033	DS DP U-1700		
		9493470	Dec 12, 2033	DS DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	003	9493470	Dec 12, 2033	DS DP U-1700		
		9493470	Dec 12, 2033	DS DP U-1948		
		9493470	Dec 12, 2033	DS DP U-1949		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					>A> PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					>A> PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					>A> PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					>A> PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001					ODE	Dec 19, 2023
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002					ODE	Dec 19, 2023
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7459428	Feb 02, 2019	U-1945			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001 >A>	9561251	Jan 23, 2030	DP U-1468			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	9549938	Feb 16, 2026	U-1951			
	>A> 9566289	Feb 16, 2026	DP			
	>A> 9566290	Feb 16, 2026	U-1970			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	>A> 9572867	Nov 01, 2025	U-1320			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001				>A> NCE		Feb 28, 2022
				>A> ODE		Feb 28, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					ODE	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					ODE	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		>A> NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			>A> PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	6149054	Dec 16, 2016	DP		>A> NPP	Feb 15, 2020
	6846413	Aug 28, 2018	DP		>A> PED	Aug 15, 2020
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7988001*PED	Feb 04, 2022				
	8733341	Dec 16, 2029	DP			
	8733341*PED	Jun 16, 2030				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	>A> RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	>A> RE46284	Dec 16, 2026			U-1751	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	>A> 9593066	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		>A> D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		>A> D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	>A> 9593066	Dec 15, 2028	DS			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm